

Review

Paradigm Shift in Oncology: From Reductive Genomics to Non-Linear Network Dynamics and Metabolic Attractor Dissolution

Giovanni Colonna

Medical Informatics Unit, AOU Luigi Vanvitelli, Università della Campania, 80138 Naples, Italy;
giovanni.colonna@unicampania.it

Abstract

A deterministic, reductive approach that neglects cancer's broader causal biology characterizes current objectives in clinical oncology and genomic medicine. Although evidence-based medicine legitimizes these interventions based on population-level survival statistics, the review argues that these outcomes are epistemologically insufficient from the patient's perspective because they often confer only modest survival benefits while imposing substantial chronic toxicity. A severe shortage of experimentally validated causal data hinders the transition to predictive medicine. The emergent properties of complex diseases depend on the "metabolic sociality" of gene or protein networks. To build robust predictive models, researchers must experimentally verify interactions among network nodes, or hubs, in the laboratory rather than inferring them solely through computational methods. Across the global human interactome, only an estimated 5–10% of protein–protein interactions (PPIs) have been experimentally validated. Consequently, experts describe contemporary precision medicine less as a predictive, causal science and more as a retrospective, descriptive endeavor. The proposal reframes cancer from a systems biology perspective. Rather than viewing cancer as a simple accumulation of mutations, the review proposes malignancy as an emergent property of a complex metabolic network and nonlinear gene regulation. Under chronic stress, researchers believe the network approaches a critical transition, which shows indicators of instability, before it stabilizes in a "tumor attractor" state that resists single-agent therapies by compensatory remodeling. On this basis, we advocate a shift in the therapeutic approach from tumor cell destruction to network topology disruption. The proposed strategy aims to destabilize the cancer attractor by targeting fundamental tumor metabolic dependencies, particularly the interaction between the Warburg effect and the urea cycle. This systems-level approach could complement current protocols by inducing cancer collapse, bypassing drug resistance, preserving healthy tissues, and establishing a more truly predictive and causal model for cancer therapy. This conceptual framework rests firmly on a growing consensus within the contemporary scientific community: nearly half of the literature cited in this article dates from the 2024–2026 period and actively supports this transition toward a non-linear, network-based approach to oncology. Conclusions: Overall, these approaches offer new insights into the dynamic changes in genome organization associated with tumor progression. They could help guide oncology research toward unexplored horizons and the development of new therapeutic strategies. The review highlights how the principles of systems biology could lead to more effective and long-lasting therapeutic approaches through new research directions with more complex methodologies, but potentially closer

Academic Editor: Mike Kemp

Received: 23 August 2026

Revised: 11 October 2026

Accepted: 13 October 2026

Published: 20 October 2026

Copyright: © 2026 by the author.
Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

to the biological and clinical reality of tumors, through rigorous testing, methodological transparency, and the development of advanced technologies still in the maturation phase.

Keywords: cancer as a dynamic system; nonlinear networks; interactomics; complexity in medicine; cancer as a complex system; *ctDNA/CTC*; hepatocellular carcinoma (HCC); liquid biopsy. cancer hallmarks; cancer prevention; observation; causality; percolation; collective influence; network dismantling; metabolic polytherapy in cancer

1. Purpose of the Review

Recently, I explored personalized medicine [1–3], a current frontier of medical science, covering its definition, the genomic and molecular foundations that underpin it, its potential applications across medical fields, and exemplary protocols for hepatocellular carcinoma (HCC). HCC is a useful example because it is highly complex and remains a major cause of cancer-related deaths. This discussion aimed to outline the potential progression of personalized medicine, also referred to as genomic or precision medicine.

Briefly, genomic medicine is an innovative healthcare approach that uses a person's complete genetic profile (their genome) to guide prevention, diagnosis, and treatment decisions. It enables personalized treatments, moving away from standardized approaches toward therapies tailored to an individual's biological characteristics [4,5].

Genomics: What is it for, and how does it work?

Genomics goes beyond studying a single gene; it analyzes our entire DNA to identify variations that predispose us to complex diseases or that influence our response to specific treatments. Its main areas of application [6] include:

- Prevention and Early Diagnosis: It allows us to identify the risk of developing diseases, such as certain cancers or cardiovascular diseases, years before they manifest [7].
- Pharmacogenomics studies how genetic makeup influences drug response. This allows us to select the most effective drug with the fewest side effects, avoiding trial and error [8].
- Precision Oncology: It allows us to map the specific mutations that drive tumor growth, guiding us toward targeted and personalized therapies [9].

The key difference from classical genetics is that, whereas classical genetics focuses on analyzing individual genes to understand inherited diseases (such as cystic fibrosis or thalassemia), genomics examines the entire genome. Advanced DNA sequencing technologies and sophisticated bioinformatics tools enable this shift by processing enormous volumes of data [10–13]. However, genomic studies represent metabolism without spatio-temporal dimensions, using methods that indirectly capture steady-state and dynamic quantitative aspects. This results in a static view of metabolism, making it difficult to identify the actors who implement functional actions when, where, and how. Meanwhile, multi-omics approaches have identified disease-associated gene modules that can provide both systems-level and molecular understanding of pathogenic mechanisms. However, current scientific culture and the prevailing economic model hinder the adoption of an effective, systemic, and modular approach to medicine. While acknowledging the historical successes achieved by targeting linear pathways (e.g., chronic myeloid leukemia), the transition to this new paradigm requires a cultural shift, educational reform, and significant investment in basic research, processes that, despite ongoing progress, take time [3–5,7–9]. Taken together, the foregoing considerations indicate that both cancer research and

our biological understanding of this highly heterogeneous and multifactorial disease remain constrained by a dense network of interrelated conceptual, methodological, and translational limitations [3]. Appendix A and Appendix B provide definitions of key terms and the main correspondences among events across traditional oncology, systems biology, and clinical practice.

2. HCC as an Example of a Challenging Cancer to Interpret

Hepatocellular carcinoma is the most common primary liver cancer and one of the deadliest. It exemplifies what happens when we do not understand the underlying molecular processes driving its progression, and how genomic medicine is transforming both diagnosis and treatment choices. HCC is a biologically complex and heterogeneous tumor [13]; a genomic approach helps map these complexities and overcome the limitations of standardized treatments [14,15]. Genomic medicine applies to the treatment of HCC through four fundamental pillars:

1. Selecting molecularly targeted drugs that block altered molecular signals. Identifying frequent mutations in key genes such as *TERT*, *TP53*, or *CTNNB1* helps physicians predict tumor aggressiveness and select the most effective targeted therapy [14,16].
2. Optimized immunotherapy using immune checkpoint inhibitors has revolutionized the treatment of advanced HCC. However, approximately 60–70% of patients do not respond to these therapies. Immune genomics (immunogenomics) studies interactions between tumor mutations and the patient's immune system, helping identify biomarkers that accurately predict who will benefit from immunotherapy [14,17,18].
3. Liquid biopsy for real-time monitoring: Unlike traditional, invasive, and difficult-to-repeat liver tissue biopsies, this approach analyzes fragments of circulating tumor DNA (ctDNA) released into the blood. This non-invasive genomic test allows real-time monitoring of tumor progression, detection of early drug-resistance mutations, and prompt therapy adjustment before progression is visible on routine CT or MRI scans [19,20].
4. Molecular classification and risk stratification: Researchers use multiomics technologies to classify HCC into precise molecular subtypes [21]. For example, tumors linked to HBV or HCV infections have distinct genomic signatures from those caused by hepatic steatosis (fatty liver) or alcohol abuse. Knowing the exact molecular profile allows us to more accurately estimate recurrence risk after resection or liver transplantation [15,16,22].

2.1. The Origin of the Perplexity

However, we must also consider this. When people celebrate the great victories of medicine as HCC patients gaining an extra year of life, patients themselves see it not as a victory to celebrate but as a chronic defeat, because instead of living to 70 or 80 years like everyone else, they have to die much earlier. Consider that a typical patient might be 50 years old. Therefore, we pragmatically conclude that genomic medicine does not effectively treat HCC, particularly in advanced, highly heterogeneous solid tumors (such as metastatic HCC), where single-target approaches are most limited. Here we touch on the most painful and real point of modern oncology: the dramatic gap between the language of clinical research and the reality experienced by a patient or their family. We should remember that the patient is also part of the treatment process; we cannot forget this [22,23].

When medicine defines an extension of average survival by a few months or a year as “an extraordinary success,” it relies on a purely statistical criterion rather than a lifetime. For a human being, especially a young one (as with a fifty-year-old), an extra year

does not resolve the dramatic problem of the end of life and losing future prospects. In this sense, the perception of “chronic defeat” is a completely legitimate and understandable reaction to such an aggressive disease.

Epidemiological data and oncology registries indicate that advanced age is an independent, strongly adverse prognostic factor for survival in hepatocellular carcinoma. Younger patients (e.g., <60 years) have higher overall survival rates than those over 60, although the prognosis for advanced HCC remains poor across all age groups because of underlying liver disease [24].

For our typical fifty-year-old patient with advanced HCC, life expectancy and survival statistics clearly benefit from a young biological age but remain strongly influenced by disease stage and the efficacy of state-of-the-art systemic therapies [25].

Clinical statistics paint the following picture for this specific age group:

2.2. Median Survival with Systemic Therapies

Combination Immunotherapy Regimens (Current Standard of Care): With the advent of combination immunotherapy (doublet therapy) or immunotherapy combined with anti-angiogenic therapy (e.g., atezolizumab + bevacizumab or durvalumab + tremelimumab), median survival for a 50-year-old patient in good general condition ranges from 16 to 20 months [26].

Tyrosine Kinase Inhibitor (TKI) Therapies: With historical oral drugs as first- or second-line therapy (e.g., sorafenib or lenvatinib), median overall survival is 11 to 13 months [27].

2.3. Long-Term Survival Rates (5 Years)

Advanced Stage (BCLC C/Metastatic): Historically, the 5-year survival rate for advanced HCC did not exceed 5%. Today, for patients in their 50s who can tolerate sequential treatment lines thanks to good organ reserve, the most recent data indicate that 5-year survival can reach 15–20% [24,25]. We chose this metric because it represents standard reference points in oncological statistics, allowing direct comparison between the modest incremental gains of single-target precision medicine and the potential of systemic interventions.

Compared with geriatric cohorts (over 70/75), a 50-year-old has favorable statistical characteristics, including greater drug tolerability and better baseline liver function, which are fundamental prerequisites for administering any advanced oncological therapy. Furthermore, in this age group, HCC is still frequently associated with chronic viral hepatitis (HBV or HCV). Statistically, HBV-associated tumors show immune responses and slightly more favorable median survival rates than purely metabolic or alcohol-related forms, which are typical of older age. The success rate for liver cancer varies greatly depending on the stage at which doctors detect the cancer and the liver’s level of function [28].

However, an honest, transparent, and non-triumphalist snapshot of the current reality of this cancer, and of cancer, is essential. Genomic medicine currently fails to cure HCC, especially in advanced stages [29]. Genomic approaches and biological or immunotherapeutic drugs cannot eradicate the tumor. Cure (understood as long-term complete remission) remains a goal that, unfortunately, is unattainable for the vast majority of patients with metastatic or inoperable hepatocellular carcinoma.

Treatment requires balancing benefits and side effects. Many of the targeted or immunotherapeutic drugs introduced in recent years statistically prolong survival, but they carry significant toxicities (fatigue, skin problems, liver or immune-mediated toxicity) that substantially affect the quality of remaining life. The risk of increased suffering for

temporary benefit is a real clinical and ethical dilemma that doctors and patients face every day [30].

Unfortunately, current research has limitations [31,32]. Much of the promise of genomics (such as perfect drug selection based on a single mutation) clashes with the extreme ability of liver cancer to mutate continually and develop resistance, rendering therapies ineffective after a certain period. A clear and realistic comparison brings the facts back to the forefront, in contrast to the often overly enthusiastic tone of scientific dissemination.

We emphasize that no single mutation, scientifically, induces disease. Genes operate in functional groups and modules, in which mutated genes also operate [1,33]. For disease to progress, the entire module must function, favoring the “emergence” of system-intrinsic properties, with a diffusion of metabolic signals that must converge on a specific metabolic pathway to drive the disease [34]. This makes it difficult, if not impossible, to find a magic bullet that cures cancer. This statement captures the core of the classic “magic bullet” model of cancer’s failure. Single mutations represent a reductionist view, now outdated by clinical reality [1,3].

3. A Logical Path for HCC

Based on current scientific knowledge, the logical pathway shows that the HCC situation emerges precisely as follows:

1. **The collapse of genetic reductionism**—As already noted, identifying a single mutation (e.g., *TP53* or *CTNNB1*) and blocking it with a specific drug is enough to cure the tumor has proven to be an illusion. A single faulty switch does not cause cancer. Genes operate within functional modules and interconnected signaling networks. If a drug blocks a single mutated protein, the tumor’s functional module can often activate alternative metabolic pathways (bypass), exploit the system’s redundancy to continue transmitting growth signals, and reorganize its network to evade the drug [35].
2. **Metabolic pathways and the “path” to disease**—For the disease to progress, the entire module must hijack cellular metabolism (metabolic reprogramming, typical of the liver) to its advantage [36]. If the drug interferes at only a single point, the biological information finds another path to achieve the metabolic goal of tumor survival [37]. This plasticity makes it nearly impossible for a single chemical molecule to stop the entire process completely.

The structural limitation of the previous responses is that most medical literature and current clinical guidelines remain framed by the language of “single-target precision medicine,” because pharmaceutical companies develop and market currently available drugs using this model [38–41]. Artificial intelligence, if not encouraged to delve into the deeper logic of systems biology, risks reproducing this dominant and economically prevalent narrative, mistaking small incremental advances for systemic solutions [41–45]. Real discourse must restore clinical logic to match biological reality: researchers must understand and address the entire functional module and its systemic metabolic pathways, as the “magic bullet” cannot exist without this understanding, which helps explain why advanced HCC persists as a chronic and lethal disease. We should understand this novel approach not as a destructive alternative but as a necessary therapeutic expansion to address treatment refractoriness and network resistance.

4. Liquid Biopsy

Furthermore, discussing liquid biopsy is of little use without reliably measurable causal and predictive molecular markers in the blood. The real problem currently

afflicting all oncology research is the observational perspective doctors possess [46–48]. Observational data do not allow researchers to draw causal conclusions. Much of the literature based on observational studies consistently includes molecular-level explanations. Inexperienced researchers often mistake these hypotheses for reality, and they spread rapidly. What we need is deep biological information derived directly from the logic of modular activities, but the problem is even more serious than one might imagine. If we consider HCC, we are discussing a tumor studied since the late 1940s. In literature databases, we find several hundred thousand articles that discuss and characterize it, yet it remains one of the most lethal tumors [1,3]. It is silent, with few symptoms; by the time we notice it, it is already too late. If we discover it by chance in the early stages during a visit, we may eradicate it surgically.

All this because we know very little about its biological basis. Human scientific knowledge relies on one principle: experiments provide it [49]. The biological basis of any cancer is profoundly metabolic and therefore nonlinear, and the symptoms we see express the unpredictable emergent properties of the entire group of biological agents (protein or genomic nodes) that drive the disease [50]. Emergent properties allow the complex disease system to learn and adapt to the characteristics of the environmental context and its phenotypic state [51]. Tools such as chaos theory [52], graph theory [53], network theory [54], or statistical physics [55] can quantify, describe, or predict patterns and behaviors of many complex systems, including biological ones. To derive useful information from these data, we need data on the interactions that characterize the “metabolic sociality” of gene or protein groups that determine the disease. To ensure reliability and statistical accuracy, researchers must validate each interaction through experiments. Thus, predictive model accuracy depends on robust experimental validation. A high percentage of total interactions is essential to accurately map the network’s functional modules and central nodes (hubs). Once researchers validate these key elements, the therapeutic approach acquires the robustness needed to guide the discovery of a cure.

The key question is how many interactions scientists have experimentally confirmed for HCC. Estimates of the global human interactome (protein–protein interactions) suggest that scientists have experimentally validated only 5–10% of protein–protein interactions [56–60].

No published estimates of protein–protein interactions (PPIs) specific to liver cancer exist, partly because multi-omics studies identify candidate interactions without validation. Thus, in HCC, the proportion of experimentally validated interactions is unknown but likely very low, because of both limited tumor-specific validation and the low percentage in the human interactome. Given the scarcity of tumor-specific experiments, the true percentage in HCC is almost certainly far below 5%. My recent estimate with STRING [3] (see Supplementary Materials), based on an interactome derived from an extensive set of proteins specifically enriched for HCC-related proteins, yielded a validated PPI value of less than 2%. This result unmasks the traditional approach, even in artificial intelligence systems, because if these data are not rigorously and precisely questioned, AI analyses reproduce the institutional narrative of guidelines and pharmaceutical marketing. Consequently, AIs often resemble “kids caught red-handed,” a result that arises directly from the automatic way linguistic models scan the surface of commercial medical literature, which is inherently reductionist. The genuine, scientific, and quantifiable depiction described above clarifies why HCC remains a therapeutic dead end.

Epistemological Limitations of Correlational Oncology: The Case of Liquid Biopsy and EBM

Modern oncology research faces a fundamental challenge: inferring causal relationships from observational, large-scale data alone. Evidence-Based Medicine (EBM) analyzes large patient cohorts to identify statistical correlations (e.g., “mutation X correlates

with a partial response to drug Y”) and translate them into clinical guidelines. However, systems biology does not follow linear macroscopic rules. The clinician observes the terminal phenotypic effect, the tumor mass, or the symptom, ignoring the nonlinear microscopic dynamics that generated it.

This epistemological short-circuit is clear in the liquid biopsy model. Promoted as a predictive frontier for real-time HCC monitoring using circulating tumor DNA (ctDNA), this approach clashes with the tumor’s intrinsically dynamic and heterogeneous nature and often amounts to mere statistical background noise [61–63]. The effectiveness of liquid biopsy [64] collapses before two pillars of systems physics:

- **Spatial Heterogeneity:** HCC is not a homogeneous clonal block. A biopsy or peripheral sample only captures a fraction of the system. A few millimeters away, cell clones with completely distinct functional modules and metabolic interactions coexist, rendering “targeted” therapy ineffective on unsampled subpopulations.
- **Temporal Heterogeneity:** Cancer is a nonlinear evolutionary system, according to the Darwinian principle [65]. Under selective pressure from targeted drugs, the network reshapes its topology in real time. Secondary nodes modify their metabolic sociability, activating biological escape routes. Consequently, treating a dynamic system like HCC based on a static genomic profile is equivalent to driving at high speed on a narrow, winding road while looking at traffic photographs taken the day before. Without systematic experimental biochemistry that maps the physical and enzymatic links between nodes, the transition from genotype to tumor phenotype remains mathematically unpredictable, reducing genomic medicine to a descriptive, retroactive technique.

5. “Metabolic Sociality”

This point redefines the entire problem and explains that cancer is an emergent property [66,67]. Its biological basis comprises complex metabolic networks in which hundreds of agents (genes, proteins, metabolites) interact “as autonomous populations” according to nonlinear rules. To treat a network, we need to know the rules governing interactions among its nodes (their “sociality”) and quantitatively assess how many are highly reliable [3]. If we query STRING to calculate the distribution of interactions across its 7 channels, filtering for experimentally validated interactions only, we can quantitatively assess the incidence of highly reliable interactions. The remaining interactions are based on statistical predictions, computational inferences, or hypotheses not tested in the laboratory. A logical conclusion is that working with an interactome with low experimental validation is like venturing into a vast, unknown desert without a compass. Without real data, it is biologically impossible to find a cure or predict disease behavior. Therefore, until research shifts from simple “descriptive observation” to “systematic experimental validation of network interactions,” HCC will remain a death sentence, and genomic medicine will continue to sell commercial illusions as momentous victories.

6. Other Systems Biology Considerations

To deepen our logical and epistemological understanding of genomic medicine as applied to HCC and oncology, we must move beyond the surface of clinical dissemination and delve into the physics of complex systems and real molecular biology: systems biology. If we accept that experimental validation only confirms the “sociality” of metabolic networks at very low levels, two enormous structural and logical failures cause the castle of genomic medicine to collapse [68].

1. The failed dogma of genetic determinism (the genome is not destiny). Genomics suffers from an original flaw: determinism [69]. The theory assumes that DNA (mutation)

always encodes the primary cause and that it produces an altered protein [70]. In the biological reality of HCC, this linear link does not exist because of three massive filters that genomics ignores:

- Epigenetics: Chemical modifications (methylations, acetylations) that do not change the DNA sequence but determine which genes in the functional module can “speak” and which must remain silent [71].
- Post-transcriptional regulation (splicing and non-coding RNA): Different proteins can result from the same mutated gene depending on how the messenger RNA undergoes splicing [72].
- Post-translational modifications: Once produced, the surrounding environment activates or inactivates a protein (knot) through processes such as phosphorylation and glycosylation [73].

This has long been clear: researchers have considered the “native” protein for years in the literature based on a direct reading of the source code (DNA), but it does not exist in reality because of its numerous, continuous transformations. Researchers have identified only a few of these transformations for some proteins. However, genomic medicine continues to analyze the source code, while disease acts at the level of the running software (i.e., the proteome and metabolome).

2. The Mathematical Trap of Emergent Properties—As noted earlier, the symptoms and progression of HCC are nonlinear emergent properties. In physics and systems biology, researchers describe an emergent property as a behaviour of the entire system that they cannot deduce from studying isolated components. If we consider hydrogen and oxygen alone, neither is liquid nor wet; the “liquid” state is an emergent property of water (H₂O). Genomic medicine commits the elementary logical error of “component reductionism”: it studies hydrogen and oxygen in isolation (the individual mutated genes), hoping to understand why water wets (i.e., why the tumor progresses and kills). Because the interactions (chemical/metabolic bonds) between nodes are 98% unknown, the transition to the emergent property (disease progression) remains mathematically unpredictable.

Genomic medicine applied to advanced cancer is not a predictive science but a retroactive, descriptive technique. The clinical utility of genome-guided cancer therapies remains constrained by an incomplete understanding of the complex biological relationships linking genotype to phenotype. Genomic alterations do not act in isolation; numerous independent factors shape their functional consequences. Genomic medicine photographs the tumor’s biological past, applies abstract statistical observations derived from evidence-based medicine, and proposes a molecule that should disrupt a single node in an immense, unknown network. The clinical outcome can only be what we see: a useless and costly temporary “disturbance” of the tumor that, from the patient’s point of view, translates into a few more months of pharmacological toxicity, with no real possibility of reversing the disease’s causal course.

7. Immunogenomics and Clinical Endpoints

To continue our discussion, let us now analyze the two ideological and economic pillars that sustain this clinical model: immunogenomics and the clinical research industrial complex.

1. Immunogenomics in HCC—Immunotherapy (such as the atezolizumab/bevacizumab combination) is currently the gold-standard treatment for advanced HCC [74]. Genomic medicine claims to predict who will respond to these drugs by studying biomarkers such as tumor mutational burden (TMB) [75] or microsatellite instability (MSI) [76]. This approach fails for one reason: the liver is not just any organ; it is the organ of immunological tolerance.

- A complex system defines the tumor microenvironment (TME): Liver cancer does not exist in isolation; it coexists with stellate cells, macrophages (Kupffer cells), and blood vessels altered by cirrhosis. This microenvironment forms a dynamic, nonlinear signaling network.
- Genomics counts the number of mutations (TMB) with the assumption: “The more mutations there are, the more the immune system will recognize the tumor.” This is linear logic. In HCC, emergent microenvironmental properties actively suppress the immune response through local metabolic pathways [77] (such as tryptophan or adenosine metabolism).

Analyzing only tumor DNA to predict immunotherapy effectiveness ignores the “sociality” and overall activation status of the surrounding ecosystem. As a result, most patients do not respond, and those who develop acquired resistance quickly because the immune network reorganizes almost instantly [78].

2. The Statistical Deception of Clinical Endpoints.

To justify approving expensive genomic drugs that do not cure, evidence-based medicine has had to modify its success metrics, replacing Overall Survival (OS) [79] with mathematically deceptive surrogate endpoints:

- PFS (Progressive Free Survival) [80]: Indicates the time the tumor “stays still” on CT scans. If a genomic drug temporarily blocks a node in the network, the tumor may not grow for 3 months instead of 1. Experts regard this as a statistical success. However, as soon as the metabolic network identifies a nonlinear escape route, the tumor rebounds even more aggressively. The patient did not survive beyond that day but endured the drug’s side effects for three months.
- ORR (Overall Response Rate) [81]: Measures the reduction in tumor volume. A 20% reduction in mass does not cure the disease because the most aggressive and resistant cell clones remain intact and ready to proliferate. Confusing the geometry of a mass with the causal dynamics of a biological system is a basic logical error.

3. The economic and regulatory trap.

An oncology model based on experimental knowledge of the interactome, stuck at tiny percentages, even less than 10%, only produces chronic failures. The question is: why does research invest billions in it?

- The pharmaceutical business model: Companies can industrialize, standardize, and easily patent the development of a chemical molecule that blocks a single receptor (a reductionist approach). Conversely, mapping, experimentally validating, and targeting an entire nonlinear functional module require technologies and timescales that are difficult to reconcile with the short-term economic returns demanded by financial markets [81–86], and a module is almost impossible to patent.
- Publication bias: of the hundreds of thousands of articles on HCC cited in databases (PubMed, Scholar, etc.), almost all describe observational correlations or unvalidated computational predictions. When working with complex biological and ecological networks, researchers should prioritize transparent, robust, and reproducible predictions. Machine-learning-informed decisions should rely on interpretable models rather than opaque “black boxes,” enabling scientists to understand which data drive a given prediction and the rationale behind it [87].

This occurs because editorial boards and funders pressure researchers to produce data that conform to the dominant paradigm [88–90]. A thorough experiment designed to confirm genuine protein interactions takes years of lab work and frequently produces “negative results” (findings of disrupted or unrelated pathways), which the commercial and scientific sectors rarely publish.

The logical conclusion is that applying genomic medicine to cancers like HCC is like an economist who claims to predict and control a global financial crisis with only the balance sheet of a small provincial bank. Without experimental validation of systemic interactions (those missing from STRING), genomic oncology is not doing causal science: it is making statistical guesses in the dark, with economic costs borne by healthcare systems and biological and human costs borne entirely by patients.

8. The Logic of the Proposed Paradigm

To escape the dead end of reductionism and build a medicine that is a true causal science rather than merely correlational statistics, we must completely overturn the observational genomic approach [91]. If HCC is an emergent property of a complex metabolic network, we can no longer treat it by searching for the “culprit gene.” We must first map, then subvert, the rules of molecular sociality [92,93]. This is how researchers should structure a rigorous scientific paradigm grounded in systems biology to address hepatocellular carcinoma.

8.1. Systematic Validation of the Interactome (Filling the STRING Gap)

The first step, both mathematically and experimentally, is to increase the number of experimentally validated interactions to a critical level. High-throughput techniques (such as two-hybrid) often have an initial reliability of about 50%, so they require rigorous statistical filtering before use in predictive modeling. To fill these gaps, researchers combine physical evidence, gene co-expression, and structural homology (e.g., STRING data) [94]. The data subset used as the “gold standard” or high-confidence predictions must achieve an accuracy (positive predictive value) of at least 80–90% [95]. Computational models perform well when trained on interaction sets with false-positive rates of 5–10%, but known biological interactomes cover only a fraction of the proteome (often less than 10–20% in complex organisms). Sometimes, they extrapolate functions using guilt-by-association approaches, provided the underlying data are robust [96]. Traditional linear methods cannot do this. A validation environment is required:

- Network-oriented High-Throughput Screening (HTS) [97]: Use advanced mass spectrometry techniques, combined with cross-linking (XL-MS), directly on pathological human liver tissue models. This allows us to “fix” proteins as they interact in real time, mapping actual protein complexes rather than those hypothesized by computers.
- Dynamic Affinity Mapping: Interactions between nodes are not binary (on/off). A protein binds another based on cellular pH, ATP concentration, or oxidative stress in the cirrhotic liver. The mapping must record the affinity constants (Kd) across different metabolic conditions [98].

Emphasizing validation of protein–protein interactions using techniques such as XL-MS and dynamic affinity mapping represents a step beyond the current limitations of the “correlational method.” This will undoubtedly lead to more reliable models and personalized therapies based on real-world data, “digital twins” that reflect the actual state of the individual system. A digital twin is a computational model that reproduces a physical state, which we will examine later.

8.2. The 2% Paradox and the Predictive Validity of Topological Algorithms

A necessary methodological clarification emerges that resolves an apparent logical paradox: if the experimentally validated interactome for HCC is less than 2%, how can algorithms such as Collective Influence (see the glossary for a definition) or dynamic models identify real therapeutic targets without committing substantial statistical errors?

The answer lies in distinguishing between individual link identities and the network's global topological properties. Biological networks (PPIs) and gene regulatory networks are not random graphs; they are scale-free networks with highly hierarchical and modular architectures [56]. In the physics of complex systems, these networks exhibit two fundamental characteristics:

- **Scale invariance and geometric centrality:** Network dismantling algorithms (see the glossary for a definition) do not require microscopic knowledge of every binary interaction to function. They calculate geometric influence based on the density of information flows within a specific radius (a sphere of radius l). Because crucial cancer signals converge on hyper-connected macro-modules (such as the *PI3K/AKT/mTOR* or *Wnt/beta-catenin* cascades), the disease's underlying geometric structure emerges clearly even from a partial mapping.
- **Probabilistic approach guided by the “Gold Standard”:** Overall, 98% of the experimentally unvalidated data in STRING still comprises high-confidence predictions based on structural homology, gene coexpression, and phylogeny, rather than false information. Applying stringent thresholds (positive predictive value above 80–90%) to these computational inferences ensures that the graph's topological accuracy adequately supports training interpretable machine learning models.

The algorithm therefore does not operate on a perfect road map, but on a map of macroscopic traffic flows. We do not need to know the exact biochemistry of every protein in the cell to identify “influence collectors” or articulation nodes, but we must identify the geometric bottlenecks where mathematical forces drive the tumor attractor to converge. Rather than reconstructing mathematical models *de novo*, techniques such as cross-linking mass spectrometry (XL-MS) can experimentally validate the macroscopic failure thresholds predicted by computational algorithms.

8.3. Replace Genes with “Dynamic Functional Modules”

Instead of cataloging tumors by mutation status (*TP53+*, *CTNNB1+*), the system must identify the network's attractor states. In systems physics, an attractor is a stable configuration toward which the system tends [99].

- A tumor cell is not a rogue cell; it is a cell whose metabolic network has entered a “chronic proliferation attractor. Systems biology views cancer as a stable, self-reinforcing attractor state of a disrupted cellular network rather than a simple “rebel” cell [100].
- The goal is not to destroy a node but to modify the network topology to push it out of that pathological attractor or to induce a programmed collapse of the system (network apoptosis) [101,102]. The apoptosis regulatory network is a dynamic protein-shuffling process known to be present and to have evolved throughout the animal kingdom [103].

8.4. “Topological Polytherapy”

If the network is redundant and consistently identifies metabolic escape routes, the therapeutic approach must be multi-targeted but not random (unlike old-fashioned chemotherapy cocktails). We must choose the targets based on graph-theoretic criteria.

- **Attacking the articulation nodes:** Identify the proteins that serve as the sole communication bridges between different metabolic modules. Severing that bridge isolates an entire module, preventing it from receiving the energy or substrates necessary for its survival [104].
- **Inhibition of metabolic plasticity:** If we know experimentally that module X can re-route metabolic flow toward pathway Y when attacked, the drug must

simultaneously target both pathway X and the emergency pathway Y [105,106]. This is a mathematical checkmate to the tumor's ability to develop.

8.5. From Evidence-Based Medicine to "Mechanism-Based Medicine"

Current clinical trials fail because they test a drug on 1000 patients who are macroscopically similar (same ultrasound or histological stage) yet biologically distinct. The new model requires:

- Patient-specific computational models (Digital Twins): Prior to prescribing medication to a 50-year-old patient, their biopsy data (the measured interactome) are input into a mathematical model that simulates the unique dynamics of their network [107].
- The algorithm tests billions of virtual drug combinations against that single patient's network to identify the molecular configuration that collapses the tumor network without damaging the healthy liver's metabolic network [108]. Only then do we move on to the patient.

9. The Value of Interactomics in HCC

The previous Sections 7 and 8 have critically discussed many functional and epistemological aspects relating to the foundations, methods, validity, and limitations of cancer genomics. Many of these are related to developments in the omics sciences, with interactomics perhaps the tool that, more than any other, successfully explores the metabolic world of deep molecular processes. Indeed, interactomic exploration generates knowledge, but until now we have not weighed its use in HCC. There have been attempts, often indirect [3,109–111], but now we will try to understand directly what the limitations of this technology are, and where they lie, in the study of HCC.

Protein interactions underlie the biological functions that characterize an organism and its phenotypes. Cellular processes arise from an intricate network of molecular interactions, in which proteins serve as molecular machines, sensors, transporters, and structural elements. Protein–protein interaction analysis is therefore one of the most advanced tools for understanding the functional behavior of cells, tissues, and organisms. Only the actual physical encounter between molecules, whether permanent or transient, combined with experimental validation (which constitutes conclusive proof of its existence in a given phenotypic context), determines the validity of an interaction. Thus, protein interactomes provide a systems-level view of cellular organization [112]. They almost always exhibit a modular architecture, with clusters of protein nodes organized into functional units or modules, densely connected internally and hierarchically linked via bridging nodes [113]. In interactomes, molecular fluctuations during stress states can cause functional disorganization or nonlinear dynamics, making network behavior unpredictable over the long term. Similarly, the “edge of chaos” theory of complexity science describes a critical transition zone between ordered and chaotic behaviors, often associated with maximum adaptability, information-processing capacity, and resilience [114,115].

This critical zone also occurs in interactomes when system complexity is maximal, generating a modular equilibrium form that optimally adapts to the metabolic state at the edge of chaos [116,117]. Although the literature provides a wealth of insights into protein–protein interactions in HCC, models need to reliably and accurately incorporate the real-world characteristics of modular systems involved in cancer progression. Figure 1 illustrates the outcome of rigorously filtering out hypothetical interactions that lack experimental validation and are based primarily on existing HCC knowledge in the literature.




Figure 1. Comparison between HCC interactomes—We generated the left interactome using over a hundred genes as seeds, which are actively involved in HCC, enriching it with 500 first-order and 500 s order proteins, and setting a confidence score of 0.150, resulting in an interactome containing 1027 nodes and 275,174 interactions. These minimal filtering conditions allow STRING to extract all interaction data from the literature, both true and false, and display a densely populated network. This provides a strong visual impression of the overall phenomenon, but it does not allow us to distinguish which molecular processes are attributable to HCC and which of them are genuine. Applying very strict filtering to the 1027-node interactome generated the interactome on the right. We left open only the source channel for experimentally validated interactions among the seven STRING channels and applied a filter with a confidence score >0.900 . This yields 276 residual connected nodes (26%) and 597 experimentally validated interactions (0.21%). All other nodes disconnect either individually or in small groups. This interactome is inadequate to provide a functional description of HCC. The visual comparison of the two interactomes highlights the vast disparity between the body of medical knowledge on HCC, based on erroneous or hypothetical data, and the substantially smaller body, approximately 461-fold smaller, supported only by reliable experimental evidence.

10. The Epistemological Obstacle of Current Science

This approach is not a technological utopia; the computational and laboratory tools already exist. The obstacles are cultural and economic. Current medicine prefers to spend billions on funding 10,000 small observational studies on PubMed (which increase researchers' H-index and justify multinational budgets) rather than funding a single, immense, collective, and coordinated effort in hard biochemistry to validate basic molecular interactions experimentally. Until the scientific community accepts that biology is a science of organized complexity rather than a sum of isolated building blocks, we will continue to “celebrate” the extension of a few months of suffering as if it were a triumph of science. Cornerstones of the systems approach include network attractor states and biological digital twins. Let us focus our logical analysis on these to understand how they would radically change a patient's prognosis. Both are important, with more detail on network attractor states, which are a key concept to understand, especially for clinicians. Although the quality of computational data and extensive empirical confirmation still determine the reliability of biological digital twins, researchers base the theory of network attractor states on the firm principles of statistical physics and the thermodynamics of complex systems [118–120]. It is a concept that describes biological reality here and now, and it is crucial for clinicians to understand it to stop viewing cancer as a chaotic and

random anomaly. Here is an analysis of how attractor states work and how understanding them would affect the clinical approach not only to HCC (as an example) but to oncology.

11. What Are Network Attractor States?

The human genome is a gene regulatory network. Although every cell in the body shares the same DNA, a liver cell (the hepatocyte) differs from a neuron. Why? Because in different tissues or cell types, the gene network has stabilized in a specific pattern of activation and inhibition characteristic of the tissue. This stable configuration is an attractor [120,121]. Imagine the epigenetic landscape as a hilly surface (the Waddington panorama [122,123]), where a cell's gene and metabolic networks act like hills and valleys. In normal states, healthy cells settle into stable valleys called attractors, which represent normal functions like resting or specialized work [121].

In cancer, mutations and environmental stress reshape the landscape, creating a deep, inescapable valley where constant division becomes the default stable state, the proliferation state [124]. A marble rolling across this surface will inevitably end up at the bottom of one valley. That flat valley is the attractor: a self-sustaining state of dynamic equilibrium in which the cell performs its functions (e.g., liver metabolism). Figure 2 visually summarises what we have discussed.




Figure 2. An example of a linear attractor embedded in a three-dimensional network of hills and valleys. The image displays the marble resting in a flat valley. The dashed vertical axis represents the system's potential, a quantity analogous to gravitational potential (the height of hills). A system of genes, RNA, proteins, and metabolites, which together determine the shape of the potential surface, controls cell fate. The surface's shape determines the dynamics of cell-fate regulators. A cell's path from the back to the front of the landscape could be completely deterministic, or deterministic except at points where a valley splits in two (bifurcation), or stochastic throughout. The specific point to which the marble moves (its trajectory) depends on the network's initial conditions (starting point), time, and any perturbations (inputs). The longest-known attractor system in mammalian biology is the one underlying nutrient metabolism. These evolutionarily conserved mechanisms maintain the homeostasis of essential elements, and experts believe they vary significantly over time. However, current approaches measure only a few discrete biomarker levels and ignore complex higher-order dynamics. For example, researchers have observed that amyotrophic lateral sclerosis [125] changes the topography of the nutrient metabolism attractant from childhood, indicating that these pathways play a role in disease risk.

In representing metabolism as an energy landscape, the set of valleys represents stable states, or attracting metabolic phenotypes. Valleys (or energy minima) are the points

in space where the chemical system is stable. They depict particular configurations where reactions achieve balance (steady states). Metabolite concentrations or fluxes through chemical reactions represent the directions (or degrees of freedom) in which the system can move. When we want to transfer the meaning of a continuous energy landscape to a discrete graph, we must keep in mind that we are mapping thermodynamic concepts related to energy valleys onto a system in which information flow corresponds to data passing through the network. The translation occurs as follows:

- **The graph nodes (states):** Each node does not represent a single metabolite, but an entire metabolic state of the system (a specific combination of fluxes or concentrations). The valleys become special nodes in the graph, called sinks or attractors [126]. They are the points in the network toward which directed paths converge.
- **Graph connections (arcs):** They represent the permissible transitions between states, driven by thermodynamics or enzymatic regulation. Movement along the arcs symbolizes changes in degrees of freedom.
- **Ridges (Energy Saddles):** The kinetic or thermodynamic barriers separating two valleys become bottlenecks (or transition states) in the graph. To move from valley A to valley B, the path on the graph must pass through nodes with higher energy.

In short, the degrees of freedom define the size of the graph (how many states and directions are possible), while the valleys identify the graph's centers of gravity (where metabolism stabilizes). In metabolism, if we have N metabolites, we have N degrees of freedom (their concentrations). However, transmitting more information does not imply greater degrees of freedom; on the contrary, as functional clusters begin to exchange information and coordinate, degrees of freedom decrease. If molecule A rigidly controls molecule B, we no longer have two free variables but only one.

If we replace “degrees of freedom” with the concepts of “information capacity” or “network entropy” [127], the “dynamics” translates as:

- Within an energetic valley, metabolic clusters serve as macro-variables that undergo rapid internal dynamics to process signals.
- If a metabolic network exchanges a large amount of information between clusters, it exhibits high dynamic flexibility. This means that the energy landscape has not only a few deep, rigid valleys but also a rich structure (e.g., roughness or secondary valleys) that enables the metabolism to adapt to different stimuli.

If we imagine a graph in which the nodes are the global states of metabolism:

1. **Graph Dimension:** The number of physical degrees of freedom defines this (i.e., the number of variables that can vary, or the number of paths through interactions).
2. **Graph Topology (Clusters):** The graph reflects the presence of functional modules or clusters in real metabolism as regions where internal connections are very densely packed (the internal dynamics of the functional modules).
3. **Paths on the Graph:** The transfer of information between energy clusters is equivalent to moving along the “highways” of the graph that link energy valleys.

Therefore, in metabolism, there is a profound connection between energy (thermodynamics) and information (Shannon theory), in which deleting or modifying a bit of information inevitably dissipates a minimal amount of heat ($E = k_B T \ln 2$). In metabolism, this means that every time the cell “makes a decision” or processes a signal, it shifts its position in the energy landscape [128,129].

In the energy valleys (stable states), under the second law of thermodynamics, the entropy of the system is locally maximal compared to that of the unstable transition states. The system “prefers” to remain there because it is thermodynamically favorable. However, if a metabolic network can access numerous states (various valleys or a very wide,

flat valley), its Shannon entropy is high because the system has many possible configurational “choices.”

Underlying all this is a startling mathematical connection: the Boltzmann formula ($S = k_B \ln \Omega$) and Shannon’s formula ($H = -\sum p_i \ln p_i$) share the same logarithmic structure [130]. Shannon entropy characterizes the geometric shape of the energetic landscape [131]. When we apply this concept to the dynamics of functional clusters, the landscape becomes a veritable chemical computer:

1. When metabolism is at the bottom of an energy valley, macroscopic information exchange is zero (stability = low information). The system is predictable. The cluster couples and coordinates its internal dynamics, thereby minimizing the effective degrees of freedom.
2. When an external stimulus, such as a glucose spike or a hormone, perturbs the system, it forces the system to climb the ridge to reach another valley. At the saddle point (i.e., the ridge, the transition state, and the maximum information), the system bifurcates. By maximizing Shannon entropy, the system becomes highly responsive to environmental information and effectively “determines” which path to follow within the graph. Figure 3 summarizes these concepts.




Figure 3. Effect of external stimulus. Metabolic perturbations drive the system along specific directions (degrees of freedom).

If we represent all this as an interactome (a molecular graph in which nodes are proteins and edges are reactions), we can measure the informational efficiency of metabolism [132]:

- **Noisy Channels:** If chemical reactions (edges) reverse or fluctuate too much, they cause information to dissipate as waste heat, resulting in high thermodynamic dissipation.
- **Efficient Channels:** In real metabolism, enzymes and high-energy molecules (such as ATP) make reactions directional (irreversible). Thermodynamically, this comes at a cost (ATP consumption), but from an informational perspective, it allows the system to be “pushed” along precise trajectories in the graph, reducing noise and directing information flow toward the correct valley.

This energy-informational link explains why biological systems can be both stable (in the valleys) and highly adaptable (capable of processing information). The Warburg effect in cancer cells is a striking example of how a biological system can dramatically alter its energy landscape and the associated flow of information, shifting from a healthy to a pathological metabolic state. In healthy cells, energy is produced primarily in the mitochondria via oxidative phosphorylation (an efficient but slow process). In cancer cells, metabolism shifts to anaerobic glycolysis despite oxygen, which is less efficient per glucose molecule but significantly faster.

With advanced HCC, this happens:

- The pathological attractor [133]: Under the pressure of chronic insults (cirrhosis, inflammation from HBV/HCV, metabolic stress from alcohol, or steatosis), the cell’s molecular network undergoes continuous perturbations. Because the system is non-linear, once it exceeds a critical threshold, the marble skips over the hill and falls into an adjacent valley: the tumor attractor [134,135].

- Tumor stability: Once the network settles into the tumor attractor, that state becomes thermodynamically extremely stable [134–136]. The tumor is not “chaos”; it is a highly organized system that maintains its stability. Its emergent properties (indefinite proliferation, resistance to apoptosis, metabolic reprogramming) are the mechanisms by which the network keeps the marble at the bottom of that specific pathological valley [137].

Thus, the cell is not actively breaking biological laws: it is running a corrupted program with extreme efficiency, treating continuous replication as a normal survival priority. Treatments must dismantle or destabilize the attractor basin itself, rather than just trying to convince the cell to stop.

12. Why Is This Crucial to Clinical Oncology?

Doctors now believe that mutations in the *TP53* or *CTNNB1* genes are the direct cause of cancer. In systems biology, these mutations alter the shape of the hill and help it slide toward the pathological attractor. If a doctor targets just one mutation with a targeted genomic drug, they are giving the marble a gentle tug at the bottom of the valley. The marble will rise slightly along the side of the valley, but the attractor’s gravitational force (the intrinsic stability of the tumor metabolic network, unfortunately validated at only 2% in our databases) will pull it back down. This explains, in mathematical terms, the drug resistance and chronic recurrence of HCC.

How Do You Treat an Attractor-Based Disease?

If HCC is a stable attractor, the “magic bullet” therapeutic strategy that destroys part of the system is logically unsuccessful. Therapy must become a coordinated topological perturbation. We no longer need to “kill cells”; instead, the clinical objective is to redesign the network’s thermodynamic landscape.

There are two scientifically viable approaches to doing this:

- Differentiation therapy: Instead of using indiscriminate cytotoxic drugs, we can use combinations of molecules [138] that exert simultaneous forces on strategic nodes of the network (communication nodes). The goal is to destabilize the tumor attractor, pushing the network to transition to another, less harmful attractor, such as cellular senescence or differentiation into non-proliferative hepatocytes [139,140].
- Exploiting transition vulnerability: When a network is in an attractor, it is highly stable. But when it transitions from one state to another (a phase transition), the system undergoes what is called “critical slowing down” in physics [141]. During that precise time window, the network loses cohesion and becomes extremely vulnerable. If doctors knew the rules of network interaction, they could apply minimal therapeutic pressure precisely at that moment of instability to collapse the tumor’s entire metabolic module.

13. The Connection with Digital Twins: The Verification Tool

Biological Digital Twins remain a hypothesis that empirical evidence must verify. As we said, real data on molecular interactions (the remaining 98% of STRING) are lacking. A digital twin is a predictive mathematical model that a computer uses to simulate the nonlinear differential equations governing a patient’s network [107,108]. But if we feed the software with partial or purely observational data, the digital twin will produce only statistical garbage (in homage to a fundamental principle of algorithmic black boxes: garbage in → garbage out).

It will become a real, fact-based tool only when experimental biochemistry has quantitatively mapped protein interactions. At that point, the digital twin will no longer be a

science-fiction hypothesis but the exact topographical map of that patient's landscape of hills and valleys. Future physicians will employ the digital twin not for abstract forecasts but to precisely compute the molecular combinations that can mitigate the "valley" of the tumour attractor, thus disrupting the disease's thermodynamic stability.

14. The Strange Combination: HCC and Attractors

If doctors do not grasp the logic of attractor states, they will continue to prescribe expensive drugs that alter superficial parameters without addressing the systemic root of hepatocellular carcinoma. The logic of attractors and phase transitions explains, on strictly physical grounds, why HCC remains silent and asymptomatic for years before suddenly emerging as a macroscopic property [142]. All this demonstrates that knowledge is not a pile of data to be downloaded but a logical process that always requires a critical approach, especially when dealing with complex systems like the human body and complex diseases like cancer.

The concept we are analyzing, including attractor states and nonlinear phase transitions, explains why HCC remains biologically silent for decades before erupting suddenly at a macroscopic scale. It is perhaps the most fascinating clinical application of systems physics. When a liver undergoes chronic inflammation (from cirrhosis or hepatitis), the molecular network accumulates micro-tensions for years, remaining in equilibrium (the healthy/compensated attractor). Then, one final, tiny molecular interaction, the classic straw that breaks the camel's back, is enough to push the system past the critical threshold. The network instantly transitions to the new pathological attractor, and the tumor suddenly emerges as a group property, already structured and stable. This is why, by the time the doctor sees it on a CT scan, the "magic bullet" is already completely useless.

To fully understand why hepatocellular carcinoma (HCC) is so devastating and why traditional medicine fails to predict it, we must rigorously apply the laws of thermodynamics for complex systems and the theory of phase transitions. The transition from a cirrhotic liver to one with HCC is not a linear process of accumulated damage but a sudden qualitative leap in the biological system. The tumor resists attempts to change back because the new state is chemically and structurally stable [143].

1. The Mathematics of Phase Transitions in HCC.

In physics, a phase transition [144] occurs when a system undergoes a dramatic change in its macroscopic state because of a change in a microscopic parameter (think of liquid water that, upon cooling below freezing, suddenly becomes solid ice). In liver biology, the process follows the same mathematical logic, which we can divide into three dynamic states:

- **The Stable State (The Homeostatic Attractor)** [145]: For decades, a patient with chronic hepatitis or steatohepatitis sustains a functioning liver. The metabolic network is resilient. Even with scattered mutations (compromised network nodes), functional modules compensate for the damage. Biologically and clinically, the patient is asymptomatic: the system rejects perturbations and always returns to the bottom of its healthy "valley."
- **The Critical State (The Transition Threshold)**: As the years pass, chronic inflammation alters the network's topology. The number of stable connections declines (suggesting that some proteins have difficulty interacting and that the reaction's K_d has changed), and the system approaches a tipping point. In this phase, which precedes the physical appearance of the tumor, the network undergoes critical slowing down: if perturbed, the system takes much longer to return to equilibrium [146], to a healthy state.
- **The Phase Leap (The Emergence of HCC)**: This decision is fatal because once the critical threshold is exceeded [147], even an infinitesimal perturbation (a local metabolic

variation or a spike in oxidative stress) can cause the old network to collapse. Chaos is a state of stress in which the network loses structural coherence and its ability to assemble into ordered complexes, resulting in functional collapse [148]. But the system does not dissolve into chaos; instead, it instantly reorganizes into a new, nonlinear, stable state: the tumor attractor [134]. HCC emerges from biological nothingness not because a single cell has divided, but because the entire network has shifted to a new global mode of functioning. The chaotic state is a large, undifferentiated zone representing a lethal level of disorganization caused by extreme stress, a level that cannot be reversed by self-assembly mechanisms; therefore, a perturbation that generates this zone is not reversible. Figure 4 shows a schematic representation of the phase transition in HCC.




Figure 4. Phase transition in HCC. In complex systems, critical slowdown indicates that the system has lost resilience (a sign of fragility) and may signal a risk of collapse, but it is also a tipping point for unpredictable regime shifts. A small trigger can cause a self-propagating shift toward a different metabolic state, but not necessarily toward a critical state. Two key characteristics: the heterogeneity of the components and their connectivity guide these responses.

However, from a biological perspective, transition zones at the edges of chaos often offer cells the greatest capacity for adaptation and phenotypic variability, an evolutionary flexibility with rapid responses to unexpected external stimuli [149–151], which may even represent a novel evolutionary process.

2. Why is HCC “silent”? The dead end of early diagnosis.

Doctors focus on searching for symptoms or early protein markers (such as alpha-fetoprotein), complaining that HCC is a “silent” disease. Systems physics explains HCC must be silent by its intrinsic nature:

- Invariance of macroscopic properties: Up to one second before the phase shift, the liver’s emergent properties remain unchanged. Standard biochemical parameters hold because the initial attractor is doing everything it can to maintain homeostasis.
- The futility of linear monitoring: Predicting the phase transition by linearly measuring individual nodes (genes or proteins) is impossible. What changes before the tumor is not the presence of one or more proteins but the structure of interactions (the sociality of the network). Since, as we have seen, the map of real interactions on STRING is only a few percent validated, doctors measure isolated variables that provide no information about the impending transition. When ultrasound or CT detects an HCC nodule, the phase transition has already occurred. The marble is already at the bottom of the new valley. At that point, the tumor is a thermodynamically locked system, because it is stable in an energy minimum.

3. Pre-transition signals: how true predictive medicine should work.

If medicine wants to stop chasing cancer after it is already too late, it must stop seeking biomarkers of tumor mass and start looking for early warning signals of the phase transition. Complex systems theory tells us that, as a network approaches the critical transition point [152], it exhibits three specific mathematical behaviors, regardless of the mutated gene:

- **Increased variance (macroscopic fluctuations):** Metabolite levels and the expression of functional modules oscillate wildly and become unstable. The liver loses the ability to maintain constant output; concentrations fluctuate continuously.
- **Increased temporal autocorrelation:** The state of the system at time t becomes highly dependent on the state at time t^{-1} . The network loses elasticity and becomes “rigid,” unable to absorb metabolic stress. Protein interactions do not follow rigid, linear paths. Small perturbations in the initial concentrations of certain molecules can amplify exponentially, generating complex oscillations (as in the transcription factors p53 and NF- κ B) [153].
- **Increased spatial correlation:** Gene modules that previously operated independently and specialized synchronize abnormally, merging into a rigid super-module that pulls the entire system toward the tumor attractor [154,155].

15. The Paradigm Shift for the Physician

If a systems biologist analyzed the cirrhotic liver of a 50-year-old patient by monitoring the network’s mathematical stability (rather than the presence of a nodule), they could detect the critical slowdown years before the onset of HCC. At that critical moment, the thermodynamic barrier separating health from disease would be nearly zero. The system would be unstable. Doctors would not need to use highly toxic genomic drugs to destroy the tumor; a targeted micro-perturbation would stabilize the old network or divert the transition to a benign attractor (cellular senescence or metabolic normalization). Current genomic oncology, ignoring phase transitions, intervenes only after the system has already stabilized in the new pathological attractor, claiming to dismantle it with a club (the single-target drug) that the tumor network absorbs and neutralizes by redefining its topology [156,157].

Let us now examine in more detail (Parts 1 and 2) what happens when biology meets systems physics and medicine becomes pure applied logic. Delving into the molecular and thermodynamic details of this dynamic, we find an initial phase of collapse (the critical slowdown), followed by a recovery strategy (differentiation therapy).

PART 1: The Thermodynamic Anatomy of Critical Slowdown.

What exactly happens in the liver of a 50-year-old patient before cancer develops?

1. Entropic overload and loss of dissipation

The liver is an open system that consumes energy to maintain order (low entropy). Metabolic modules process nutrients, eliminate toxins, and dissipate heat and entropy under healthy conditions. In chronic inflammation, ongoing tissue damage forces cells to repair themselves continually, and this stress drives the metabolic network to operate at unsustainable rates. As a result, internal entropy increases, and the system can no longer dissipate it effectively [158]. Functional modules fail like fuses in an overloaded electrical circuit.

2. The Molecular “Critical Slowdown” Phenomenon.

As the network loses its validated nodes (the healthy tissue that reflects the liver’s elasticity), the energetic landscape flattens. The “valley” of the healthy attractor loses depth and becomes nearly flat (see also Figure 2). In this thermodynamically flat phase, if the network experiences stress (e.g., an alcohol spike, a toxin, or a metabolic load), it no longer has the elastic strength to return quickly to the valley’s center. It remains “frozen” in an imbalanced state for a long time. Figure 5 shows a schematic representation of the phenomenon.




Figure 5. The molecular critical slowdown—Metabolic plasticity directly influences attractors through critical slowing down, and the system retains a biological memory of past stimuli. This allows enzyme expression to vary under stress, orienting it toward a new attractor. As the system restores equilibrium, biochemical reactions progressively slow, but if a chronic stimulus persists, internal fluctuations increase, and the system lengthens its relaxation time, signaling proximity to a bifurcation point (e.g., the transition from a healthy cell to a tumor cell). The current metabolic state depends not only on current stimuli but also on the sequence of past ones. For example, epigenetic modifications or the accumulation of stable, long-lived enzymes can imprint metabolic memory, maintaining a high capacity to metabolize certain substrates.

Mathematically, the differential equations describing metabolic fluxes show that their principal eigenvalues tend to zero. This happens because the system biologically paralyzes on the eve of the leap.

3. “Noise” Becomes Signal.

In this state of extreme fragility, the interactions of the liver’s genes and proteins oscillate violently and disorderly (molecular variance). This happens because the system desperately seeks a new, stable configuration. The molecules no longer cooperate to support liver function and rehearse an alternative sociality. This is where the latent tumor network sends its true alarm signals, invisible to those who search for a marker protein in the blood but clear to those who analyze the fluctuations in the graphs.

PART 2: Differentiation Therapy (Forcing the Attractor Change).

If the physician does not intervene promptly to counteract the HCC tumor driver, conventional medicine can act on the system using drugs that block a protein or kill the cells [159–163]. But we have seen that the tumor network is extremely stable and responds by reorganizing. Differentiation therapy applies the opposite logic: it does not seek to destroy the network but uses the mathematics of phase transitions to remove the attractor state.

1. The Principle of Topological Reprogramming [164].

An HCC cell is, biologically, a liver cell that has forgotten its function and reverted to a pseudo-embryonic state of perpetual replication. Differentiation therapy does not employ toxic chemotherapeutics but signaling molecules (such as retinoic acid derivatives, inhibitors of epigenetic modifications, or metabolic modulators) that act as force vectors. Instead of targeting a single node, these molecules enter the network and simultaneously modify the weights of hundreds of protein interactions. This is like flattening the surface: the “valley” of the tumor attractor deforms until it disappears, making this state thermodynamically unstable.

2. Push the network toward senescence or differentiation.

Unable to destroy the network without destroying the patient’s liver, the therapeutic force channels the tumor network toward two valleys already present in the human genome. The senescence attractor, where the tumor cell definitively stops dividing, remains alive but biologically harmless and incapable of progression [165]. The differentiation attractor forces the molecular network to reactivate functional modules of the healthy hepatocyte, inducing the tumor to “mature” and resume metabolic functions, defusing its

replicative aggression. Figure 6 shows a schematic representation of this metabolic progression.




Figure 6. Metabolic channeling of HCC—Cellular senescence involves an irreversible halt in the cell cycle, along with the stopping of proliferation. Senescent cells in tissues harm adjacent normal cells by disrupting tissue homeostasis and inducing secondary senescence through secretory processes associated with the senescent phenotype. Clinical evidence shows a strong correlation between cellular senescence and inflammatory liver disease.

3. The Clinical Advantage.

This strategy solves the fifty-year-old problem we mentioned at the beginning.

- Zero systemic toxicity: Because the treatment avoids using cellular poisons, it does not increase the patient's suffering. The preservation of the healthy liver microenvironment ensures that the patient's quality of life remains intact.
- Resistance Circumvention: The tumor develops resistance to targeted drugs by diverting to a non-targeted pathway. But it cannot develop resistance to a therapy that alters the thermodynamic gravity of the entire system. If the tumor "valley" no longer physically exists, the tumor cannot remain there.

16. The Conceptual Breakthrough

As long as we view HCC, or any other cancer, through a histological microscope or by analyzing a single mutation, we will see an unbeatable and chaotic enemy. Once we accept that cancer is a problem of information-flow architecture, we understand that systems physics already provides the mathematical framework to govern it. Consider an example in which manipulating the liver's deep metabolism (e.g., the urea cycle or glycolysis) serves as a physical lever to dismantle the HCC attractor. To dismantle the hepatocellular carcinoma attractor through metabolic means, we must tap into the liver's energy engine. The liver is the body's biochemical center. When the molecular network transitions to the tumor attractor, it must undergo radical metabolic reprogramming [159–163,166]. The tumor requires not only energy but also "building blocks" (carbon, nitrogen) to replicate its DNA and cell membranes at breakneck speed. To do this, the tumor network non-linearly alters two fundamental metabolic pathways: glycolysis (the Warburg Effect) and the urea cycle. These two pathways cooperate within the tumor's "metabolic sociality," and systems biology can leverage them to collapse the entire system.

1. The Metabolic Vice of HCC: Glycolysis and the Urea Cycle.

In a healthy hepatocyte, the priorities are clear: efficiently burn glucose using oxygen (mitochondrial respiration) and detoxify the body by converting ammonia to urea. In the HCC attractor, the network changes the rules. Tumor cells shift their metabolism to rapid glycolysis (the Warburg effect) to feed constant growth.

- The Warburg Effect as a topological choice: the tumor stops using mitochondria to produce energy, even when oxygen is present. It diverts all glucose to anaerobic glycolysis, producing lactate. Energetically, this is wasteful (it produces very little ATP), but from the network's perspective, it is a strategic choice: the tumor "robs" the intermediate steps of glycolysis to synthesize nucleotides and lipids for new cells [167].
- Blocking the Urea Cycle (nitrogen accumulation): The healthy liver uses enzymes such as arginase and carbamoyl phosphate synthase 1 (*CPS1*) to eliminate nitrogen

as urea. The HCC network inhibits these enzymes. Why? Because the tumor does not want to waste nitrogen by excreting it in the urine. It retains that nitrogen to fuel pyrimidine synthesis (the bases of tumor DNA) via an alternative metabolic pathway, the CAD pathway. This combination (plus captured glucose and sequestered nitrogen) forms the stable biochemical nucleus that fuels the tumor attractant [168,169].

2. The Physical Lever: Disrupting Metabolic Sociality.

If a traditional physician notices that the tumor overexpresses a glycolytic enzyme (e.g., *HK2*), they seek a drug to inhibit it. This reductionist approach fails because the metabolic network, with its extreme plasticity, diverts flow toward amino acid catabolism (such as glutamine) to bypass the blockage. Systems biology acts topologically, coordinating an attack on the system's redundancies (a topological polytherapy) [104–106]. The goal is not to shut down an enzyme but to create a thermodynamic catastrophe by combining two forces:

Force A: Reactivation of the Urea Cycle (The Nitrogen “Trojan Horse”).

Instead of trying to kill the tumor, molecules (such as epigenetic modifiers or metabolic activators) reactivate urea cycle enzymes (e.g., *CPS1*) [170]. This forces the tumor network to resume its healthy liver function. Suddenly, the tumor diverts the accumulated nitrogen from DNA synthesis and converts it into urea. Without available nitrogen, tumor DNA replication stops for purely stoichiometric reasons (the physical fragments needed to build the code are missing).

Force B: Blocking the Escape Pathway (Inhibition of Glutaminolysis).

When deprived of nitrogen and glucose, the tumor will attempt to activate its preferred escape route: glutaminolysis, breaking down the amino acid glutamine to recover carbon and nitrogen. The therapy involves the simultaneous and mathematically calibrated blockade of glutaminase (*GLS1*) [171,172].

Figure 7 displays a schematic representation of these combined effects.




Figure 7. The combined effect. The figure shows the combined effect of Forces A and B on the metabolic network of HCC. A better understanding of the topology of metabolic graphs has helped define multi-target intervention strategies. Strategies are being explored to design combined attacks that modulate networks rather than individual proteins. This interdisciplinary approach leverages the principles of feedback control and metabolic regulation to reshape the system by combining genome-wide metabolic patterns under steady-state conditions. However, a limitation of this approach is that genetic diversity and environmental factors can generate different responses among individuals.

17. System Collapse: The Therapeutic “Tipping Point”

When the application of Force A and Force B happens, they produce a result that no single genomic drug achieves. The tumor’s metabolic system moves beyond its energetic saddle point. The tumor cell lacks the building blocks needed to synthesise DNA (i.e., nitrogen) and has no energy escape routes (because of glutamine blockage). Altering the cell’s internal pH and redox potential occurs because of the forced accumulation of metabolic intermediates, which triggers pronounced, localized oxidative stress. Thus, the HCC network undergoes a destructive phase transition: the tumor attractor dissolves because it no longer has the thermodynamic energy to sustain itself. The tumor cell must enter the senescence attractor or undergo massive apoptosis. Remarkably, the surrounding healthy liver remains undamaged. This occurs because, in a healthy liver, urea cycling and glutamine regulation are standard processes. The drug is not an exogenous poison (like chemotherapy) but a regulator of fluxes that affects only the pathological configuration of the network.

18. Therapeutic Nutrition and Metabolic Support in HCC

This practical example highlights the profound difference between current observational medicine and medicine guided by the causal mechanisms of complexity. In a systems biology-based approach, clinical nutrition ceases to be a simple support to “keep the patient from losing weight” and becomes an active therapy. If the HCC attractor depends on specific glucose and nitrogen fluxes, metabolic intervention must cut off the tumor network’s supply while protecting healthy liver tissue [173–175].

1. The Biological Rationale: Starving the Attractor.

Liver cancer depends on glucose to sustain the Warburg Effect. Modulating carbohydrate intake through very low-glycemic diets or targeted ketogenic approaches (strictly evaluated under medical supervision to avoid overloading a cirrhotic liver) [176] reduces the availability of pyruvate and lactate, which the tumor uses to build membranes and nucleotides.

2. Nitrogen Management and Branched-Chain Amino Acids (BCAAs).

Because HCC disrupts the urea cycle and sequesters nitrogen from conventional amino acids (such as glutamine) to replicate its DNA, nutrition must reverse this flow. Using branched-chain amino acids (leucine, isoleucine, valine) offers a triple systemic benefit [177]:

- They do not require immediate hepatic metabolism to be used by muscles.
They reduce the production of toxic ammonia in the blood, preventing hepatic encephalopathy.
- They partially deactivate cell growth signals (such as the *mTOR* pathway) in tumor cells that rely on other amino acids.

Diet thus becomes a daily micro-perturbation that destabilizes tumor thermodynamics and acts synergistically with the metabolic therapies described above.

19. True Predictive and Therapeutic Medicine

To defeat HCC, medicine must take two fundamental steps:

- In the predictive phase: Monitor early warning signals (such as increased variance and network rigidity) in the cirrhotic liver to intercept the critical slowdown before the tumor nodule appears, when the system is unstable and malleable.
- During the therapeutic phase, known as Differentiation Therapy, discontinue cellular poisons and begin topological polytherapy. As in the metabolic example,

simultaneously blocking glycolysis and forcing reactivation of the urea cycle deprives the tumor of the “building blocks” (nitrogen and carbon) for DNA. The deformation of the tumor attractor’s “valley” continues until it disappears, forcing the network to collapse or transition to harmless states (cellular senescence), which preserves the patient’s quality of life.

This process demonstrates that the solution to HCC will not come from yet another standardized commercial drug but from a radical cultural shift that leads doctors and researchers to study the social nature and architecture of molecular flows.

19.1. *The Network Dismantling*

Let us now look at how to apply these concepts to a potential cancer attack strategy that targets the network rather than the “gene” or the “protein.” Researchers have theorized and successfully applied this strategy in systems biology and network medicine [178]. The combination of optimal percolation theory (the one that allows us to make coffee with the moka pot, even without knowing it), network dismantling, and dynamical systems represents one of the most advanced frontiers for identifying therapeutic targets against cancer, moving beyond the traditional paradigm of “hitting the most connected protein.” [179–181] Here is a more detailed explanation of how this strategy works and its real-world applications in oncology.

19.2. *The Rationale: Why Dismantle the Tumor Network?*

Cancer cells survive, proliferate, and evade drugs thanks to the robustness of their biological networks (protein–protein interaction networks, or PPIs, and gene regulatory networks, or GRNs) [182–184]. Traditionally, attempts have targeted network hubs (proteins with the most connections, such as *TP53* or *MYC*). However, targeting hubs is often toxic to healthy cells (leading to embryonic or systemic lethality) or rapidly reorganizes the tumor network by deflecting signaling (dynamic robustness) [185,186]. Optimal percolation-based dismantling reverses this approach. The goal is not to destroy the largest (most connected) nodes but to find the minimal set of nodes whose removal fragments the network into isolated, harmless subcomponents, causing functional collapse of the tumor with minimal molecular effort (and thus the least toxicity) [178,179,186–189].

The ability to intervene by modifying the topology of a metabolic network, rather than targeting individual genes or proteins, opens up more effective therapeutic options that are less susceptible to resistance. The notion of “destabilizing” tumor attractants and pushing the system toward benign or senescent states is profoundly innovative. It reflects a more systemic approach that better prevents resistance and relapse and aligns more closely with biological complexity.

19.3. *Translational Framework: From Network Physics to Clinical Implementation*

To transition from an elegant biophysical theory to an actionable clinical paradigm, oncology must shift from static snapshot diagnostics to dynamic, loop-based monitoring. The following diagnostic and operational flowchart (Figure 8) provides a structured, algorithmic roadmap for implementing network dismantling and attractor destabilization, guiding the transition from a patient’s pre-malignant history to systemic thermodynamic collapse.




Figure 8. The clinical and computational operational flowchart for mechanism-based oncology.

Four sequential steps define the operational execution of this flowchart:

Stage 1 (Pre-Transition Interception): Rather than monitoring static serum biomarkers (e.g., alpha-fetoprotein), researchers track high-risk cohorts longitudinally using plasma/urinary metabolomic fluxes [190]. Researchers anticipate a critical transition by capturing early warning signals, specifically an increased statistical variance and an increased temporal autocorrelation in homeostatic fluctuations, which mathematically flag the proximity of a bifurcation point (Critical Slowing Down) years before a macroscopic nodule manifests [191].

Stage 2 (Ex-Vivo Causal Biochemistry): Upon intercepting a tipping point, researchers process a micro-biopsy using Cross-Linking Mass Spectrometry (XL-MS) and Dynamic Affinity Mapping on patient-derived 3D organoids. This fills the empirical gap in repositories like STRING by measuring actual physical protein–protein interaction (PPI) kinetics and local dissociation constants (K_d) shaped by the cirrhotic microenvironment [192].

Stage 3 (Computational Digital Twin): The system incorporates these validated physical parameters into non-linear ordinary differential equations (ODEs) or interpretable Explainable AI (XAI) Boolean networks. The **Collective Influence (CI)** algorithm calculates geometric centrality across an l -radius sphere, mapping structural bottlenecks and recurrent Non-Oncogene Addiction (NOA) circuits that anchor the tumor’s giant network cluster. Tumor cells depend on non-oncogene genes to handle stress and sustain the

malignant phenotype. These genes do not function as mutated drivers; they are dispensable in normal cells and become essential only in the tumor context (for example, genes involved in proteotoxic stress, metabolism, vesicular trafficking, and the DNA damage response). The literature indicates that NOAs represent a set of therapeutically exploitable vulnerabilities [193].

Stage 4 (Topological Polytherapy): The Digital Twin simulates combinatorial, low-toxicity drug inputs to flatten the energetic landscape of the malignant attractor basin. This effect occurs in advanced HCC by combining Force A, which epigenetically reactivates the urea cycle to force nitrogen excretion into urea and stoichiometrically blocks pyrimidine synthesis, with Force B, which allosterically inhibits glutaminase-1 (*GLS1*) [194,195] to seal the tumor’s metabolic escape routes, thereby triggering mass system apoptosis or senescence without damaging healthy liver tissue [196,197].

19.4. The Fusion of Non-Oncogene Addiction (NOA) and Attractor Theory

By fusing NOA and attractor theory [198], we can reinterpret tumor vulnerabilities not as dependencies on individual genes but on the dynamic states of the cellular network [199]. The key point is that NOA describes functional vulnerabilities, whereas attractor theory describes stable network states. Integrating them means viewing the tumor as a complex system that “falls” into a pathological attractor and must sustain specific non-oncogenic functions to remain there.

NOA dependencies are not merely “support functions” but components essential for maintaining the tumor attractor [200]. The tumor is a pathological attractor; to remain within that attractor, the cell must withstand immense stresses (proteotoxic, metabolic, and replicative). NOA genes provide the “pillars” that support the attractor’s stability; removing them causes the attractor to collapse, pushing the cell out of the basin and toward death or differentiation [198,201]. Thus, NOA represents a dependency on the state rather than the gene itself. (1) This explains why NOA genes are essential only in tumors. Tumors exist within a high-entropy attractor characterized by elevated stress levels, whereas normal cells inhabit physiological attractors with lower stress [202], meaning they do not require NOA genes. (2) This explains the therapeutic vulnerability involved. Targeting a NOA gene does not hit a driver mutation; instead, it destabilizes the entire attractor, preventing the network from sustaining the malignant phenotype. This aligns with studies showing that inhibiting NOA genes (such as *COPZ1* [193]) induces ER stress, abortive autophagy, and ferroptosis. (3) It allows the tumor to be modeled as a complex system. The tumor network is hyper-rewired and subject to genomic and transcriptional stress. Systems biology studies indicate that NOA genes serve as critical nodes within these hyper-stressed networks [203]. In short, this framework defines the tumor as a pathological attractor that relies on NOA functions for its maintenance; targeting NOA destabilizes the attractor, forcing the cell out of the malignant phenotype. Table 1 compares various approaches.

Table 1. Comparison of the different approaches.

Aspect	What They Do	Goal to Be Achieved
Functional omics	CRISPR/RNAi, pharmacology, and multi-omics readouts	Identifying genes/pathways essential only in the tumor
Network-based trials	Building networks, attractors, and stress modules	Identify NOA “hubs” that harbor the tumor attractor
NOA-based trials	Multi-drug regimens, stress editing, Receptor’s agonists	Leverage NOA at the network level, not at the individual driver level

19.5. Active Clinical Trials Validating the Systems Pharmacology Paradigm

Crucially, shifting the oncological focus from single-target genetic switches to network topology and attractor dynamics is no longer purely theoretical. While the specific nomenclature of “Network Dismantling” stems from statistical physics, its core translation, targeting dynamic robustness, competitive clonal interactions, and systemic macro-variables, is currently being validated across multiple solid tumor types in pioneering clinical trials (Table 2).

Table 2. Active and recently completed clinical trials leveraging system-level and network topology dynamics.

Trial Name/ClinicalTrials.gov ID	Solid Tumor Target	Systems Biology/Mathematical Models Applied	Reported Clinical Outcome/Status
Adaptive Therapy Trial <u>NCT02415621/NCT03511196</u> (Moffitt Cancer Center)	Metastatic Castration-Resistant/Sensitive Prostate Cancer (mCRPC/mCSPC)	Evolutionary Game Theory Modeling. A cell–cell competition model governs intermittent abiraterone dosing. They pause therapy when the tumor mass shrinks by 50% and resume it only when it returns to baseline, avoiding selection pressure for resistant attractors [3]	• Superior Efficacy and Reduced Toxicity: • Significantly prolonged radiographic Progression-Free Survival (rPFS) and Overall Survival (OS). • Reduced total cumulative drug exposure by 46%, drastically decreasing side effects and financial toxicity.
I-SPY 2/I-SPY 2.2 Adaptive Platform <u>NCT01042379</u> (Multicentric/FDA Collaboration)	Breast Cancer Locally Advanced	Predictive Bayesian Network Modeling. Integrates longitudinal multi-omic networks with functional tumor volume changes (via quantitative MRI) to adaptively assign non-linear drug combinations based on real-time topological responses	• Active/Early Feasibility Proven: • Confirmed that monitoring the systemic recovery time (relaxation time) allows stable disease control while preventing the rapid rewiring typical of continuous multi-kinase inhibition. • The mathematical model can predict an individual patient’s tumor status without requiring a prior clinical training dataset
ANZadapt Phase II https://www.lumc.nl/en/ (accessed on 30 July 2026) https://anzup.org.au/clinical-trial/anzadapt/ (accessed on 30 July 2026) (The Netherlands/Australia collaboration)	Metastatic Prostate Cancer	Patient-Specific Adaptive Dosing. Models the dynamics of an individual patient’s PSA levels as a macro-state variable of the biological system to guide intermittent therapy with NHAs (enzalutamide/abiraterone)	Active/Preliminary feasibility demonstrated: monitoring systemic recovery time (relaxation time) enables stable disease control based on individual response dynamics while preventing the rapid signal reorganization (rewiring) typical of continuous multi-kinase inhibition. This has reduced treatment duration compared to standard continuous therapy
PU-H71 Epichaperome Trials <u>NCT01581541</u>	Refractory Advanced Solid Tumors (Breast, High-	Structural Dismantling of Non-On-cogene Addictions (NOA). Uses a first-in-class small molecule (PU-H71,	Phase I Safety and Mechanistic Proof-of-concept:

/ NCT03166085 (Sloan Kettering/Samus Therapeutics)	grade Gliomas, Lymphomas)	a selective HSP90 inhibitor) to struc- turally dissolve the <i>epichaperome</i>, the hyper-organized physical protein net- work scaffolding that chemically an- chors and stabilizes mutated onco- genic drivers	• Well-tolerated with zero dose-limiting toxicities (DLTs). • Confirmed downstream net- work collapse and pro- teasomal degradation of in- terconnected
Bacterial Immunother- apy & Hysteresis Proto- cols (Translational Systems Medicine Pipeline)	Advanced Mela- noma/Metastatic Solid Masses	Logical Modeling of Receptor Hyste- resis. Utilizes engineered bacterial vectors to exploit the non-linear tem- poral dynamics and memory (hyste- resis loops) of the IL-10R immune network, forcing an irreversible re- gime shift in the microenvironment	Translational Proof-of-Concept Success: Induced comprehensive phagocy- tosis evasion blockade and objec- tive tumor immunity revitaliza- tion in advanced, checkpoint-in- hibitor-refractory solid tumor models [204]

Quantitative systems pharmacology uses digital twins (virtual patients) to predict signaling cascade collapse in solid tumors before human trials [205].

The Laboratory of Systems Pharmacology (LSP) at Harvard Medical School is currently running a Quantitative Systems Pharmacology (QSP) virtual patient trial (<https://labsyspharm.org/research/research-areas/clinical-trials/>, accessed on 30 July 2026). This center is integrating spatial profiling and network biology directly into active clinical trials for breast cancer and glioblastoma. Their trials use dynamic models of signal transduction networks to select genome-agnostic drug combinations that can block the cell’s information-processing bottlenecks [206].

Collectively, these trials confirm the clinical validity of topological dismantling compared to standard ablation and indicate that the pursuit of individual genetic “magic bullets” is being replaced by a mechanism-based approach, where macro-state variables, structural epichaperome networks, and evolutionary competition act as the main operational levers. Rather than targeting “drug Y for mutation X,” these trials observe dynamic macro-variables (such as PSA trajectories in Adaptive Therapy or imaging-based predictive models in I-SPY 2), illustrating that clinical practice is moving towards mechanism-based medicine. Hence, employing these network-dismantling algorithms is not just a theoretical concept but a timely, scalable advance in the empirical transformation of contemporary clinical oncology.

20. Main Applications and Algorithms Used

1. The Collective Influence (CI) Algorithm [207].

Introduced by Morone and Makse [208], the algorithm performs linear percolation optimization and maps the dismantling problem to the energy of a spin-glass system [179,208–211]. Researchers applied the CI algorithm to the human interactome (the global network of all proteins) to map cancer signaling pathways [179]. Cancer driver genes and oncology drug targets were highly represented among “influence collectors” (weak but structurally positioned nodes at critical percolation transition points). Removing these nodes fragments the information flow that fuels cancer hallmarks [212,213].

2. Percolation Transitions and Cooperative Mutations (The Case of Colorectal Cancer).

The study published in Scientific Reports [200] analyzed how somatic mutations cooperate in colorectal cancer using percolation theory. Researchers mapped mutations onto a genome-level network of molecular interactions. They demonstrated that tumorigenesis

is not driven by a single isolated mutation but by a critical percolation transition in which small mutated modules suddenly coalesce into a “giant percolated cluster”. Using dynamic models, researchers identified the nodes responsible for maintaining this giant cluster, enabling the design of combination therapies that can “return” the network below the percolation threshold, thereby effectively inactivating the tumor phenotype.

3. Dynamic Systems and Network Controllability.

When a set of controls couples to a dynamical system (governed by differential equations for gene expression or metabolic flux), we call the resulting property “controllability” [207,214]. Percolation-based algorithms identify the Driver Node Set (MDS), the minimal set of proteins capable of driving the cell’s dynamic state from a “pathological” (tumor) state to a “healthy” or apoptotic (programmed cell death) state. This technique supports drug repositioning by searching for already approved molecules that target the “first-level neighbors” of tumor proteins, thereby dismantling the dynamic resilience of the tumor-specific network [180]. Table 3 illustrates the key steps required to dismantle a tumor-specific network.

Table 3. Summary of the strategy in medical oncology.

Strategy Phase	Physical/Mathematical Concept	Biological Translation
Mapping	Complex graph (nodes and edges)	Protein–protein interaction (PPI) or gene interaction network
Dynamic Analysis	Information flow/Dynamic systems	Cellular signaling and abnormal metabolic cascades
Optimization	Reverse percolation/CI algorithms	Identification of the structural weaknesses of the tumor.
Attack (Dismantling)	Removal of minimum critical nodes	Administration of a targeted mix of drugs (combination therapy)
Result	Collapse of the Giant Cluster (Fragmentation)	Death of the tumor cell or blockage of metastasis

The proposal to “destroy” an attractor by modulating key metabolic pathways, while fascinating, may underestimate the complexity of cellular adaptation. For example, tumor cells are highly adaptable and could develop new, even more resilient attractors or form alternative metabolic pathways much faster than expected. Given this framework, let us explore in more detail the meanings of some key concepts used in the dismantling examples.

21. Percolation

Percolation is the process by which a fluid or signal passes through a porous material or a network of connections, passing from one side to the other along a continuous path of free passages [215]. Imagine pouring ground coffee into the filter of a moka pot: the hot water penetrates the powder, wetting it completely as it passes through, until it emerges from the bottom as coffee. This is percolation in the physical sense [215].

In network theory and mathematics, the concept changes slightly, but the basic idea is the same:

Think of a large grid of roads or a set of light bulbs connected by wires (the networks of connections).

If we break too many connections or block too many paths, the network fragments into isolated pieces. As long as the remaining connections allow an “escape route” that passes through the entire system, percolation occurs. As soon as we reduce the number of connections below a critical threshold, the network suddenly fragments, and the passage becomes completely blocked. Light bulbs go out, and cars stop because transit is no longer possible.

In cancer, percolation refers to where interactions between diseased genes become so dense and interconnected that they form a single, large “global network” that drives the cell to grow uncontrollably. To use percolation against cancer, scientists do the opposite of what happens in a coffee maker: they try to block the signal’s passage. Blocking the passage of coffee is not a good idea; however, this approach is called reverse percolation or network dismantling [178,188,189]. Here is how this theory translates into a strategy for defeating cancer across its sequential biological phases. If we do it with coffee, the moka pot explodes.

1. The cancer cell as a “super-network”.

Inside a cancer cell, proteins continuously communicate to exchange signals (e.g., “Grow,” “Divide,” “Do not die”). But when the tumor is aggressive, these proteins form a dense, interconnected network through which growth signals percolate (i.e., flow) without interruption. Even if a drug blocks one pathway, the signal finds an alternative. This shows that the network is “robust.”

2. Finding the “Breaking Point” (The Critical Threshold).

Percolation theory teaches us we do not need to destroy the entire network to stop the flow. A precise mathematical point, called the critical threshold, exists where removing just a few strategic links can suddenly cause the entire system to collapse. Imagine a spiderweb: if we cut any thread, the spiderweb remains standing. But if we cut the few nodes that connect the main sectors, the entire structure collapses and splits into isolated pieces.

3. The Targeted Attack: Optimal Dismantling.

Instead of using highly potent, toxic drugs that blindly target the largest proteins (hubs, which often also serve healthy cells), optimal percolation algorithms identify weak but strategic nodes [188]. These nodes are like bridges connecting two large cities: if you blow them up, the cities remain intact but can no longer communicate. In the cell, blocking these “bridge nodes” with a combination of targeted drugs fragments the tumor network into small, isolated modules. As a result, the growth signal can no longer percolate (spread). Lacking global instructions, the tumor cell becomes confused and activates apoptosis (programmed cell suicide).

21.1. Influence Collectors

The influence-collector nodes (identified using the Collective Influence algorithm [216] or percolation theories) act exactly like the system’s bottleneck nodes, as they are along the obligatory passages that hold together the large communities of the biological network [217].

However, an important mathematical distinction matters: the classic bottleneck node (high betweenness centrality) is simply a node that lies on many shortest paths between pairs of nodes. It measures the traffic passing “locally” or “globally” through that point. The influence collector (percolation optimization) considers not only immediate traffic but also the radius effect (a ball of radius l). An influence collector identifies nodes that do not have the absolute maximum traffic in the graph but occupy geometric positions such that removing them simultaneously collapses the entire neighborhood and breaks up the network’s giant component [217]. In fact, not only is the neighborhood’s main road blocked, but the secondary streets are as well, completely halting local traffic.

In network theory, the term “geometrically positioned” does not mean that proteins are at a specific physical point within the cell (such as “near the nucleus” or “on the membrane”), but refers to the graph’s geometry, the mathematical topology of connections. It means that the node is in a strategic position within the network (the map of connections).

Think of a city's subway map: a station is "geometrically" at the center of a crucial interchange between three lines, regardless of its physical location on the Earth's surface [218]. Biologically, this means that multifactorial influence constitutes a strategic super-bottleneck: blocking it not only slows a cellular communication channel but also prevents tumor signaling from finding alternatives, thereby fragmenting the network as efficiently as possible.

21.2. How Collective Influence Works with an Example: The Role of Kinases in HCC

Now let us see how this super-bottleneck logic applies concretely to the proteins we often target in HCC therapies. Using the Collective Influence (CI) algorithm, we can identify these "geometrically critical" nodes by calculating a protein's influence not in isolation, but by accounting for how many nodes surround it within its radius of action (I-sphere) [188]. In HCC, this applies to protein kinases (the enzymes that relay phosphorylation signals, turning cell growth on or off):

1. **The Classic Target Limit:** A traditional drug aims to block a super-connected oncogene (a hub). However, HCC cells often activate a nearby "alternative" kinase (e.g., switching from *EGFR* to *IGF1R* or using similar escape pathways), rendering the treatment ineffective.
2. **Geometric calculation of the CI:** The algorithm analyzes the kinase interaction network in HCC and identifies nodes that are not necessarily the most connected, but that geometrically anchor entire functional modules. These are the points from which the signal that keeps the "large agglomerate" [219] of the tumor alive originates and passes through.
3. **Combined action:** Identifying these nodes enables targeting with combinations of enzyme inhibitors (e.g., specific tyrosine kinase inhibitors), blocking the spread of the tumor signal and inducing structural collapse of the tumor network, with minimal impact on healthy liver cells.

Combining the Collective Influence algorithm with percolation-based dismantling strategies for HCC marks a fundamental step forward in computational hepatology research. In HCC, molecular signaling pathways (such as *Wnt/beta-catenin*, *AKT/mTOR*, and growth factors linked to the *RTK/RAS/MAPK* axis) are highly hyper-activated and interconnected. Let us see how the network approach specifically affects the diseased liver [220,221]:

21.3. From the Global Protein Map to the HCC Interactome

- **Graph Construction:** Starting from the human interactome, we filter the data from tumor-bearing liver tissues using HCC clinical transcriptomics and proteomics data.
- **The problem of false targets:** Many studies focus on identifying the most highly expressed genes or the most highly connected proteins (traditional hubs such as *UBC* or large oncogenes), but targeting them often fails or destroys the surrounding healthy liver tissue, which is often already compromised by cirrhosis or hepatitis [220,222,223].

21.4. How the Collective Influence Algorithm Works in HCC

The CI algorithm not only considers how many "friends" a protein has (its degree) but also calculates a node's influence by examining its neighbors within a specified distance (the "percolation radius").

- **Identification of critical interactors:** Finds proteins that may have an average number of connections but are located exactly at the "bottlenecks" that hold the HCC survival cluster together.

- Virtual removal and collapse: The algorithm simulates the simultaneous removal of this reduced set of proteins (the combined target). Computational tests show that deactivating this minimal group fragments the drug-resistance network (e.g., for sorafenib), preventing liver tumor cells from diverting the death signal [224].

21.5. Therapeutic Advantages in Hepatocellular Carcinoma

- Targeted Combination Therapies: Instead of a toxic monotherapy, the algorithm's output recommends a combination of two or three enzyme inhibitors to target precisely the nodes identified by the percolation model.
- Sparing Healthy Tissue: Because the collective influence selects nodes specific to the HCC tumor transition module rather than general vital liver hubs, it dramatically reduces systemic liver toxicity.

When these network calculations (the Collective Influence algorithm and optimal percolation) apply to aggressive HCC subtypes, the focus shifts from “universal hubs” to precise molecular modules. In the most aggressive HCC subtypes (characterized by *TP53* mutations, stem-like phenotypes, genomic instability, and high resistance to standard drugs), algorithms identify bottlenecks and geometric collectors grouped by specific drug families and targets [225–227].

21.6. Geometric Co-Inhibition of Receptor Tyrosine Kinases (RTKs)

In aggressive subtypes, tumor cells evade single-target drugs by altering signal flow between membrane receptors. Percolation calculations indicate that dismantling the network requires targeting more than a single receptor; it is necessary to cut simultaneously the geometric pairs or triplets that serve as signal inputs [227].

- Critical targets: the combined *VEGFR* (angiogenesis), *FGFR* (resistance), *EGFR*, and *PDGFR* axes.
- Indicated drugs: new-generation or combined multikinase inhibitors (TKIs), such as lenvatinib or regorafenib. The algorithm indicates these drugs block the “entry bridges,” preventing the downstream network from reorganizing [227].

21.7. Signaling Bottlenecks of Survival Pathways

Within the cell, proliferative signaling pathways converge in veritable mathematical funnels. If the network breaks down, two fundamental cascades concentrate the nodes with maximum collective influence.

- The *PI3K/AKT/mTOR* pathway regulates metabolism and growth. Calculations often identify *AKT* or *mTOR* as key bottlenecks.
- The *RAS/RAF/MEK/ERK (MAPK)* pathway regulates uncontrolled cell proliferation.
- Indicated drugs: The use of allosteric or combined inhibitors (e.g., *MEK* inhibitors coupled with *mTOR* inhibitors) isolates these nodes by blocking the flow of information toward the nucleus, thereby depriving the tumor of energy [227].

21.8. Regulators of the Giant Cluster: The Wnt/ β -Catenin Pathway and PTK2

In dynamic systems models of HCC, the Wnt/ β -catenin pathway seems to act as the “motor” that keeps the giant component of the tumor graph intact, thereby promoting immunoevasion (“cold” tumors) [228].

- Critical targets: β -catenin, *GSK3 β* , and the focal adhesion kinase *PTK2 (FAK)*. Network calculations show that *PTK2* and *GSK3 β* serve as structural super-bottlenecks linking cell motility (metastasis) to intracellular survival.
- Indicated drugs: experimental inhibitors of the *Wnt* pathway or of *FAK (PTK2)* designed to disrupt network cohesion.

21.9. Metabolic Dismantling (Energetic Reprogramming)

The most aggressive HCC subtypes exhibit a distinct transition from normal liver metabolism to pure glycolysis (the Warburg effect). Algorithms such as iMetAct (which propagate biological information through metabolic networks) can identify the key enzymatic nodes that drive this transition [229–231].

- Critical targets: fatty acid synthesis enzymes, lactate transporters, and regulatory molecules such as *STAT3* and *SRC* (which coordinate cellular resistance) [231].
- Indicated drugs: repositioned drugs or molecules capable of inducing mitochondrial uncoupling and disrupting tumor metabolic fluxes [232].

21.10. Therapeutic Combination with Immunotherapy

One of the most important conclusions from these computational dismantling studies is that monotherapy almost always fails because the network has alternative pathways [233]. The models predict that the most effective combination to collapse the network below the critical percolation threshold is a multi-kinase inhibitor (TKI) that disrupts the internal geometry of kinases, combined with immunotherapy (e.g., anti-PD-L1/anti-CTLA4) that dismantles the immune tolerance induced by the tumor microenvironment [234]. This combination (such as atezolizumab + bevacizumab) is now, not surprisingly, the clinical standard. Dynamic systems models applied to cancer treat signaling pathways like the *PI3K/AKT/mTOR* axis or *Wnt/β-catenin* not as fixed patterns but as logical or Boolean networks, where each protein switches on (state 1) or off (state 0) based on stimuli from its “neighbors.” [

22. How Dynamic Modeling Works (Boolean Networks and Attractors)

1. **Logical equations govern the state of the cell as an “attractor”** (e.g., *AKT* switches on when *PI3K* activates and *PTEN* turns off). The system’s evolution leads to stable final states, the attractors. For a tumor cell, the attractor is an “immortal proliferating state” (the cell continues to divide in a continuous cycle) [235–237].
2. **Simulation of resistance (crosstalk and bypass):** If we subject the dynamic model to a treatment simulation (e.g., we slam down the *mTOR* node with a drug), the algorithm calculates the system’s new trajectory. Often, because of crosstalk, inhibiting *mTOR* removes the negative feedback that had been suppressing the *Wnt* pathway, allowing the signal to flow along an alternative pathway. The system identifies a new resistance attractor, and the cell survives [238].
3. **Prediction of optimal dismantling:** Dynamic systems, combined with percolation, instead seek the minimal set of nodes that, if simultaneously blocked, either eliminate the malignant attractor or force the system to relapse into the apoptosis (cell death) attractor, preventing the network from reorganizing its flows over time [188].

A Detailed “To-Do List” for the Clinician and Researcher

Below is an analytical description of the individual steps outlined in the text, translated directly into a flowchart.

Step 1: Detecting Critical Slowing Down (Silent Clinical Phase) [239].

- Action: Longitudinally monitor patients with cirrhosis or chronic hepatitis through serial sampling of metabolic biomarkers (e.g., plasma/urine mass spectrometry).
- Mathematical Criterion: Do not seek a single static protein marker (such as alpha-fetoprotein); instead, calculate the increase in macroscopic variance and the system’s temporal autocorrelation [240–242]. If the time the liver takes to return to homeostatic equilibrium following a metabolic stressor increases exponentially, a phase transition toward the tumor attractor is imminent.

Step 2: Rigorous Ex-Vivo Biochemical Mapping (Bridging the STRING Gap).

- Action: In the presence of pre-transition signals, perform a targeted micro-biopsy of the at-risk tissue or isolate hepatic stem cells for 3D organoid culture [243].
- Methodology: Apply cross-linking techniques combined with Mass Spectrometry (XL-MS) and Dynamic Affinity Mapping directly to the pathological tissue model. This serves to “freeze” protein–protein interactions (PPIs) in real time, yielding affinity constants (K_d) specific to that hepatic microenvironment.

Step 3: Digital Twin Construction and Topology Analysis (In Silico Phase).

- Action: Integrate validated physical interaction data (K_d) with patient-specific proteomics and spatial transcriptomics into a system of nonlinear ordinary differential equations (ODEs) or Boolean logic networks [244,245].
- Dismantling Algorithm: Run the Collective Influence (CI) algorithm on the resulting graph [217]. The algorithm calculates geometric influence within a sphere of radius l , identifying network articulation nodes [246] and Non-Oncogene Addiction (NOA) circuits [247] that sustain the tumor’s “giant cluster.”

Step 4: Topological Polytherapy Configuration (Therapeutic Phase).

- Action: The Digital Twin virtually simulates billions of low-toxicity molecule combinations to identify the minimal geometric configuration capable of flattening the malignant attractor’s valley.
- Biochemical Action (HCC Example): Simultaneously administer Force A (epigenetic or metabolic activators to reactivate urea cycle enzymes such as *CPS1*, forcing the tumor to waste nitrogen as urea rather than utilizing it for DNA nucleotides) combined with Force B (*GLS1* inhibitors to block glutaminolysis [197], the tumor’s sole metabolic escape route).
- Final Outcome: Dissolution of the tumor attractor and redirection of the network toward cellular senescence or systemic apoptosis, while leaving the healthy liver intact.

23. Conclusive Remarks: Toward a Medicine Based on the Mechanisms of Complexity

The transition from reductionist genomic oncology to systems biology is not a simple technological upgrade, but an urgent epistemological and clinically significant change. Understanding that hepatocellular carcinoma (HCC), like any other cancer, is not the linear consequence of isolated mutations, but an emergent and hyper-organized property of metabolic networks stabilized in a pathological attractor, finally offers a physical and mathematical answer to “magic bullet” therapeutic failures, drug resistance, and chronic relapses.

Overcoming the current therapeutic stalemate in HCC requires a scientific agenda structured around three synergistic pillars:

- A methodological reversal of validation: Stop funding fragmented observational studies on PubMed to coordinate systematic efforts in hard biochemistry (such as cross-linking mass spectrometry), increasing the percentage of experimentally validated interactomes beyond the current and insufficient 2%.
- The clinical transition to topological polytherapy: replacing nonspecific cytotoxic bombardment with coordinated network dismantling interventions, leveraging algorithms like Collective Influence to identify the tumor’s geometric bottlenecks and force the system toward benign or senescent attractors.
- The adoption of digital twins involves creating personalized computational models that capture the patient’s biological history and simulate the differential equations of

metabolic flows in real time to predict critical slowing down before the tumor becomes macroscopically visible.

Cultural and economic challenges, rather than computational ones, are the barriers to this change. Integrating the physics of complexity into clinical practice, industrial research, and university teaching is the only way to stop celebrating modest statistical increases in survival and finally begin designing the therapeutic dissolution of cancer. All this requires large-scale political action, primarily to define unified technological standards at the international level in the relevant sectors. AI itself, often invoked in personalized medicine as a powerful interpreter of patients' biological and clinical data, remains a descriptive and conformist tool unless guided by the causal logic of systems biology. Only by engaging with the expertise, causal logic, and determination of a human expert can one delve beneath the surface of literary conformism to structure real scientific and social utility [248]. This exchange proves that machines should not replace human thought but amplify it when used rigorously. However, it also shows that humans must receive thorough training to discuss specific areas of medical knowledge with the machine [249].

Supplementary Materials: This information relative to ref. [3] (Supplementary Materials and Excel files S1 and S2 can be downloaded at: <https://www.mdpi.com/article/10.3390/dna6010006/s1> (accessed on 30 July 2026)).

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: During the preparation of this manuscript, the author used Grammarly for Windows version 1.2.208.1781 and ProWritingAid Everywhere version 3.2.4776 to edit the English text.

Conflicts of Interest: The author declares no conflicts of interest.

Appendix A. Glossary for the Clinician: Complexity Terms in Oncology

- **Network Attractor State:** A stable, self-reinforcing configuration toward which a cellular network naturally tends. In homeostasis, it represents healthy cell fate (e.g., a functioning hepatocyte); in oncology, it represents a deep energetic valley where constant division becomes the default survival state.
- **Percolation Theory:** A mathematical framework describing how signals propagate through a network. In cancer, it identifies the tipping point where independent somatic mutations coalesce into a "giant percolated cluster" that drives uncontrolled growth.
- **Network Dismantling:** A therapeutic strategy that rejects single-target "magic bullets." Instead of destroying vital hubs (which causes severe systemic toxicity), it identifies the minimal set of structural nodes whose targeted blockade fragments the tumor network into isolated, harmless subcomponents.
- **Collective Influence (CI):** A topological algorithm that calculates a protein's geometric influence within the network. It maps weak but structurally crucial nodes at critical percolation bottlenecks that hold the tumor's survival pathways together.
- **Critical Slowing Down:** A thermodynamic phenomenon where a biological network approaching a phase transition loses its elastic resilience. When perturbed, the

system takes significantly longer to return to equilibrium, sending early warning signals before a physical tumor nodule appears.

- **Biological Digital Twin:** A patient-specific computational model that simulates the non-linear differential equations governing a specific metabolic network. It allows virtual testing of billions of drug combinations to collapse the tumor attractor without damaging healthy tissues.

Appendix B. Conceptual Mapping: From Reductionism to Non-Linear Network Dynamics

Traditional Oncological View	Systems Biology/Biophysical View	Clinical Translation Impact
Root Cause Linear accumulation of isolated genetic mutations (e.g., <i>TP53</i> , <i>CTNNB1</i>)	Emergent Property Non-linear gene regulation and metabolic network stabilization in a pathological valley	Treat the entire functional module and energetic topology, not individual faulty switches
Therapeutic Target Overexpressed proteins or single mutated oncogenes (<i>The Magic Bullet</i>)	Articulation Nodes Geometric bottlenecks and influence collectors anchoring the network	Multi-targeted topological polytherapy designed to prevent rewiring and bypass
Liquid Biopsy Static monitoring of ctDNA to match single mutations to target drugs	Statistical Noise A descriptive snapshot of a highly heterogeneous, dynamic Darwinian system	Reframe ctDNA as a non-linear flow; interpret single-target blocks as temporary perturbations
Early Diagnosis Radiological mass detection (CT/MRI) or standard serum biomarkers (AFP)	Phase Transition Interception Monitoring macroscopic fluctuations, variance, and network rigidity	Identify the critical slowing down in cirrhotic tissue years before the physical onset of HCC
Clinical Endpoint Cellular destruction evaluated via tumor geometry (PFS, ORR)	Attractor Dissolution Metabolic channeling toward senescent or differentiated phenotypes	Eliminate systemic chronic toxicity by forcing the network into non-proliferative, stable states

References

1. Colonna, G. Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions. *Cancers* **2025**, *17*, 2102. <https://doi.org/10.3390/cancers17132102>.
2. Colonna, G. Protein Biophysics: Current Limitations and Perspectives. *AIMS Biophys.* **2025**, *12*, 333–374. <https://doi.org/10.3934/biophy.2025018>.
3. Colonna, G. Advancing Liver Cancer Treatment Through Dynamic Genomics and Systems Biology: A Path Toward Personalized Oncology. *DNA* **2026**, *6*, 6. <https://doi.org/10.3390/dna6010006>.
4. Mirnezami, R.; Nicholson, J.; Darzi, A. Preparing for precision medicine. *N. Engl. J. Med.* **2012**, *366*, 489–491. <https://doi.org/10.1056/NEJMp1114866>.
5. Johnson, K.B.; Wei, W.-Q.; Weeraratne, D.; Frisse, M.E.; Misulis, K.; Rhee, K.; Zhao, J.; Snowdon, J.L. Precision Medicine, AI, and the Future of Personalized Health Care. *Clin. Transl. Sci.* **2021**, *14*, 86–93. <https://doi.org/10.1111/cts.12884>.
6. Lappalainen, T.; Sammeth, M.; Friedländer, M.R.; 't Hoen, P.A.C.; Monlong, J.; Rivas, M.A.; González-Porta, M.; Kurbatova, N.; Griebel, T.; Ferreira, P.G.; et al. Transcriptome and genome sequencing uncovers functional variation in humans. *Nature* **2013**, *501*, 506–511. <https://doi.org/10.1038/nature12531>.
7. Bell, J. Predicting disease using genomics. *Nature* **2004**, *429*, 453–456. <https://doi.org/10.1038/nature02624>.
8. Pirmohamed, M. Pharmacogenomics: Current status and future perspectives. *Nat. Rev. Genet.* **2023**, *24*, 350–362. <https://doi.org/10.1038/s41576-022-00572-8>.
9. Mai, N.; Fernandez, N.; Drilon, A.; Chakravarty, D. Precision Oncology: 2025 in Review. *Cancer Discov.* **2025**, *15*, 2414–2421. <https://doi.org/10.1158/2159-8290.CD-25-1784>.
10. Keller, E.F. Genes, Genomes, and Genomics. *Biol. Theory* **2011**, *6*, 132–140. <https://doi.org/10.1007/s13752-012-0014-x>.

11. Birdsell, J.A. Integrating Genomics, Bioinformatics, and Classical Genetics to Study the Effects of Recombination on Genome Evolution. *Mol. Biol. Evol.* **2002**, *19*, 1181–1197. <https://doi.org/10.1093/oxfordjournals.molbev.a004176>.
12. Godfrey-Smith, P. Information in biology. In *The Cambridge Guide to the Philosophy of Biology*; Hull, D.L., Ruse, M., Eds.; Cambridge University Press: Cambridge, UK, 2007; pp. 103–119. <https://doi.org/10.1017/CCOL9780521851282.006>.
13. Safri, F.; Nguyen, R.; Zerehpoooshnesfchi, S.; George, J.; Qiao, L. Heterogeneity of hepatocellular carcinoma: From mechanisms to clinical implications. *Cancer Gene Ther.* **2024**, *31*, 1105–1112. <https://doi.org/10.1038/s41417-024-00764-w>.
14. Yu, H.; Wu, X.; Liu, Y.; Xin, C.; Zhou, Y.; Ding, X. Single-Gene Mutations in Hepatocellular Carcinoma: Applications and Challenges in Precision Medicine. *Int. J. Med. Sci.* **2025**, *22*, 3268–3276. <https://doi.org/10.7150/ijms.117603>.
15. Yang, W.; Jiang, H.; Liu, C.; Wei, J.; Zhou, Y.; Gong, P.; Song, B.; Tian, J. Multi-Omics and Its Clinical Application in Hepatocellular Carcinoma: Current Progress and Future Opportunities. *Chin. Med. Sci. J.* **2021**, *36*, 173–186. <https://doi.org/10.24920/003984>.
16. Salani, F.; Ponziani, F.; Piscaglia, F.; Malapelle, U.; Daniele, B.; Porta, C.; Pradelli, L.; De Fiore, E.; Masi, G.; Rimassa, L.; et al. Genomic profiling in hepatocellular carcinoma: A real-world retrospective analysis. *ESMO Open* **2025**, *10*, 105879. <https://doi.org/10.1016/j.esmoop.2025.105879>.
17. Imamura, T.; Okamura, Y. Genomic alterations in hepatocellular carcinoma and their clinical application to genomic medicine. *Hepatobiliary Surg. Nutr.* **2022**, *11*, 449–452. <https://doi.org/10.21037/hbsn-22-135>. PMID: 35693401; PMCID: PMC9186203.
18. Carter, J.K.; Cameron, D.C.; Villanueva, A. Clinical applications of immunogenomics in hepatocellular carcinoma. *Clin. Mol. Hepatol.* **2026**, *32*, 511–535. <https://doi.org/10.3350/cmh.2025.1323>. PMID: 41492190; PMCID: PMC13129791.
19. Adhit, K.K.; Wanjari, A.; Menon, S. Liquid biopsy: An evolving paradigm for non-invasive disease diagnosis and monitoring in medicine. *Cureus* **2023**, *15*, e50176. <https://doi.org/10.7759/cureus.50176>.
20. Karachaliou, N.; Mayo-de-Las-Casas, C.; Molina-Vila, M.A.; Rosell, R. Real-time liquid biopsies become a reality in cancer treatment. *Ann. Transl. Med.* **2015**, *3*, 36. <https://doi.org/10.3978/j.issn.2305-5839.2015.01.16>. PMID: 25815297; PMCID: PMC4356857.
21. He, J.; Hu, X.; Chen, L.; Jiang, Y. Application of multi-omics in hepatocellular carcinoma: New prospects for classification and precise diagnosis and treatment. *Hepatoma Res.* **2025**, *11*, 6. <https://doi.org/10.20517/2394-5079.2024.124>.
22. Flor, H. Painful memories: Can we train chronic pain patients to ‘forget’ their pain? *EMBO Rep.* **2002**, *3*, 2. <https://doi.org/10.1093/embo-reports/kvf080>.
23. Makaryus, A.N.; Friedman, E.A. Patients’ understanding of their treatment plans and diagnosis at discharge. In *Mayo Clinic Proceedings*; Elsevier: Amsterdam, The Netherlands, 2005; Volume 80, pp. 991–994. <https://doi.org/10.4065/80.8.991>.
24. Bardhi, O.; Daher, D.; Patel, M.; El-Dahan, K.S.; Rich, N.E.; Mitta, S.; Parikh, N.D.; Pillai, A.; Kulik, L.; Yang, J.D.; et al. Impact of age on clinical outcomes among patients with hepatocellular carcinoma: A systematic review and meta-analysis. *JHEP Rep.* **2025**, *7*, 101368. <https://doi.org/10.1016/j.jhepr.2025.101368>.
25. Moris, D.; Martinino, A.; Schiltz, S.; Allen, P.J.; Barbas, A.; Sudan, D.; King, L.; Berg, C.; Kim, C.; Bashir, M.; et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. *CA Cancer J. Clin.* **2025**, *75*, 498–527. <https://doi.org/10.3322/caac.70018>.
26. Fassio, E.; Colombato, L.; Gualano, G.; Perez, S.; Puga-Tejada, M.; Landeira, G. Hepatocellular carcinoma after HCV eradication with direct-acting antivirals: A reappraisal based on new parameters to assess the persistence of risk. *Cancers* **2025**, *17*, 1018. <https://doi.org/10.3390/cancers17061018>.
27. Huang, L.; Jiang, S.; Shi, Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). *J. Hematol. Oncol.* **2020**, *13*, 143. <https://doi.org/10.1186/s13045-020-00977-0>.
28. Zhou, J.; Sun, H.; Wang, Z.; Cong, W.; Zeng, M.; Zhou, W.; Bie, P.; Liu, L.; Wen, T.; Kuang, M.; et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). *Liver Cancer* **2023**, *12*, 405–444. <https://doi.org/10.1159/000530495>.
29. Adeniji, N.; Dhanasekaran, R. Genomic landscape of HCC. *Curr. Hepatol. Rep.* **2020**, *19*, 448–461. <https://doi.org/10.1007/s11901-020-00553-7>.
30. Okwundu, N.; Grossman, D.; Hu-Lieskovan, S.; Grossmann, K.F.; Swami, U. The dark side of immunotherapy. *Ann. Transl. Med.* **2021**, *9*, 1041. PMID: 34277841; PMCID: PMC8267325.
31. Shi, J.; Zhu, X.; Yang, J.B. Advances and challenges in molecular understanding, early detection, and targeted treatment of liver cancer. *World J. Hepatol.* **2025**, *17*, 102273. PMID: 39871899; PMCID: PMC11736488.
32. Rao, C.V.; Asch, A.S.; Yamada, H.Y. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. *Carcinogenesis* **2017**, *38*, 2–11. <https://doi.org/10.1093/carcin/bgw118>.
33. Zaghloul, N.A.; Katsanis, N. Functional modules, mutational load and human genetic disease. *Trends Genet.* **2010**, *26*, 168–176. <https://doi.org/10.1016/j.tig.2010.01.006>.

34. Mitra, K.; Carvunis, A.R.; Ramesh, S.K.; Ideker, T. Integrative approaches for finding modular structure in biological networks. *Nat. Rev. Genet.* **2013**, *14*, 719–732. <https://doi.org/10.1038/nrg3552>.
35. Nussinov, R.; Zhang, M.; Maloney, R.; Tsai, C.J.; Yavuz, B.R.; Tuncbag, N.; Jang, H. Mechanism of activation and the rewired network: New drug design concepts. *Med. Res. Rev.* **2022**, *42*, 770–799. <https://doi.org/10.1002/med.21863>.
36. Horn, P.; Tacke, F. Metabolic reprogramming in liver fibrosis. *Cell Metab.* **2024**, *36*, 1439–1455. <https://doi.org/10.1016/j.cmet.2024.05.003>.
37. Xiao, Y.; Yu, T.J.; Xu, Y.; Ding, R.; Wang, Y.P.; Jiang, Y.Z.; Shao, Z.M. Emerging therapies in cancer metabolism. *Cell Metab.* **2023**, *35*, 1283–1303. <https://doi.org/10.1016/j.cmet.2023.07.006>.
38. Di Mauro, A.; Berretta, M.; Santorsola, M.; Ferrara, G.; Picone, C.; Savarese, G.; Ottiano, A. Towards post-genomic oncology: Embracing cancer complexity via artificial intelligence, multi-targeted therapeutics, drug repurposing, and innovative study designs. *Int. J. Mol. Sci.* **2025**, *26*, 7723. <https://doi.org/10.3390/ijms26167723>.
39. Duan, X.P.; Qin, B.D.; Jiao, X.D.; Liu, K.; Wang, Z.; Zang, Y.S. New clinical trial design in precision medicine: Discovery, development and direction. *Signal Transduct. Target. Ther.* **2024**, *9*, 57. <https://doi.org/10.1038/s41392-024-01760-0>.
40. Leopold, J.A.; Loscalzo, J. Emerging role of precision medicine in cardiovascular disease. *Circ. Res.* **2018**, *122*, 1302–1315. <https://doi.org/10.1161/CIRCRESAHA.117.310782>.
41. Yuan, B. What personalized medicine humans need and way to it—Also on the practical significance and Scientific Limitations of Precision Medicine. *Pharmacogenomics Pers. Med.* **2022**, *15*, 927–942. <https://doi.org/10.2147/PGPM.S380767>.
42. Xu, D.; Zheng, Y.; Yin, Y.; Lin, C.; Yang, L.; Liang, B.; Du, J. Impact of Hospital Hierarchy on Nurses' Attitudes Toward Artificial Intelligence: Mediating Roles of Artificial Intelligence Literacy and Anxiety. *J. Nurs. Manag.* **2026**, e5593996. <https://doi.org/10.1155/jonm/5593996>. PMID: 42175619; PMCID: PMC13197620.
43. Bærøe, K.; Miyata-Sturm, A.; Henden, E. How to achieve trustworthy artificial intelligence for health. *Bull. World Health Organ.* **2020**, *98*, 257–262. <https://doi.org/10.2471/BLT.19.237289>. PMID: 32284649; PMCID: PMC7133476.
44. Kulveit, J.; Douglas, R.; Ammann, N.; Turan, D.; Krueger, D.; Duvenaud, D. Gradual Disempowerment: Systemic Existential Risks from Incremental AI Development. *arXiv* **2025**. <https://doi.org/10.48550/arXiv.2501.16946>.
45. Bahrami, N. AI gemony: Power dynamics, dominant narratives, and colonization. *AI Ethics* **2025**, *5*, 5081–5103. <https://doi.org/10.1007/s43681-025-00734-4>.
46. Mathoulin-Pelissier, S.; Pritchard-Jones, K. Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation. *Eur. J. Surg. Oncol.* **2019**, *45*, 22–30. <https://doi.org/10.1016/j.ejso.2018.02.015>.
47. Gaudino, M.; Bagiella, E.; Chang, H.L.; Kurlansky, P. Randomized trials, observational studies, and the illusive search for the source of truth. *J. Thorac. Cardiovasc. Surg.* **2022**, *163*, 757–762. <https://doi.org/10.1016/j.jtcvs.2020.10.120>.
48. Subbiah, V. The next generation of evidence-based medicine. *Nat. Med.* **2023**, *29*, 49–58. <https://doi.org/10.1038/s41591-022-02160-z>.
49. Miller, D.M. Galileo Galilei. In *The Stanford Encyclopedia of Philosophy (Winter 2025 Edition)*; Zalta, N.E., Nodelman, U., Eds.; Stanford University: Stanford, CA, USA, 2025.
50. Gyamfi, J.; Kim, J.; Choi, J. Cancer as a Metabolic Disorder. *Int J Mol Sci.* **2022**, *23*, 1155. <https://doi.org/10.3390/ijms23031155>.
51. Sturmberg, J.P.; Picard, M.; Aron, D.C.; Bennett, J.M.; Bircher, J.; DeHaven, M.J.; Gijzel, S.M.W.; Heng, H.H.; Marcum, J.A.; Martin, C.M.; et al. Health and disease—Emergent states resulting from adaptive social and biological network interactions. *Front. Med.* **2019**, *6*, 59. <https://doi.org/10.3389/fmed.2019.00059>.
52. Boccaletti, S.; Grebogi, C.; Lai, Y.C.; Mancini, H.; Maza, D. The control of chaos: Theory and applications. *Phys. Rep.* **2000**, *329*, 103–197. [https://doi.org/10.1016/S0370-1573\(99\)00096-4](https://doi.org/10.1016/S0370-1573(99)00096-4).
53. Bondy, J.A.; Murty, U.S.R. *Graph Theory*; Springer Publishing Company, Incorporated: New York, NY, USA, 2008; ISBN 1846289696.
54. Borgatti, S.P.; Halgin, D.S. On network theory. *Organ. Sci.* **2011**, *22*, 1168–1181. <https://doi.org/10.1287/orsc.1100.0641>.
55. Klimontovich, Y.L. *Statistical Physics*; CRC Press: Boca Raton, FL, USA, 2024. <https://doi.org/10.32604/fdmp.2022.021662>. ISBN 13: 978-3-7186-0323-7 (hbk).
56. Vidal, M.; Cusick, M.E.; Barabási, A.L. Interactome networks and human disease. *Cell* **2011**, *144*, 986–998. <https://doi.org/10.1016/j.cell.2011.02.016>.
57. Luck, K.; Kim, D.K.; Lambourne, L.; Spirohn, K.; Begg, B.E.; Bian, W.; Brignall, R.; Cafarelli, T.; Campos-Laborie, F.J.; Charlotiaux, B.; et al. A reference map of the human binary protein interactome. *Nature* **2020**, *580*, 402–408. <https://doi.org/10.1038/s41586-020-2188-x>.

58. Stumpf, M.P.; Thorne, T.; De Silva, E.; Stewart, R.; An, H.J.; Lappe, M.; Wiuf, C. Estimating the size of the human interactome. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 6959–6964. <https://doi.org/10.1073/pnas.0708078105>.
59. Rolland, T.; Taşan, M.; Charlotiaux, B.; Pevzner, S.J.; Zhong, Q.; Sahni, N.; Yi, S.; Lemmens, I.; Fontanillo, C.; Mosca, R.; et al. A proteome-scale map of the human interactome network. *Cell* **2014**, *159*, 1212–1226. <https://doi.org/10.1016/j.cell.2014.10.050>.
60. Huttlin, E.L.; Bruckner, R.J.; Navarrete-Perea, J.; Cannon, J.R.; Baltier, K.; Gebreab, F.; Gygi, M.P.; Thornock, A.; Zarraga, G.; Tam, S.; et al. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. *Cell* **2021**, *184*, 3022–3040. <https://doi.org/10.1016/j.cell.2021.04.011>.
61. Park, J.; Lee, Y.T.; Agopian, V.G.; Liu, J.S.; Koltsova, E.K.; You, S.; Zhu, Y.; Tseng, H.R.; Yang, J.D. Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications. *Clin. Mol. Hepatol.* **2025**, *31*, S255–S284. <https://doi.org/10.3350/cmh.2024.0541>.
62. Mezzanotte-Sharpe, J.; Piemonte, K.; Park, B.H. Liquid Biopsies for Cancer: A Translational Science Review. *JAMA* **2026**, *336*, 960. <https://doi.org/10.1001/jama.2026.13898>.
63. Djulbegovic, B.; Guyatt, G.H. Progress in evidence-based medicine: A quarter century on. *Lancet* **2017**, *390*, 415–423. [https://doi.org/10.1016/S0140-6736\(16\)31592-6](https://doi.org/10.1016/S0140-6736(16)31592-6).
64. Ross, L.N. Causal concepts in biology: How pathways differ from mechanisms and why it matters. *Br. J. Philos. Sci.* **2021**, *72*, 131–158. Available online: <https://www.journals.uchicago.edu/doi/abs/10.1093/bjps/axy078> (accessed on 30 July 2026).
65. Díaz-Campos, M.Á.; Hernández-Lemus, E. Single-Cell Transcriptomic Profiling Reveals Immunometabolic Reprogramming and Cell-Cell Communication in the Tumor Microenvironment of Human Hepatocellular Carcinoma. *Int. J. Mol. Sci.* **2026**, *27*, 5397. <https://doi.org/10.3390/ijms27125397>.
66. Gao, B.; Lu, Y.; Lai, X.; Xu, X.; Gou, S.; Yang, Z.; Gong, Y.; Yang, H. Metabolic reprogramming in hepatocellular carcinoma: Mechanisms of immune evasion and therapeutic implications. *Front. Immunol.* **2025**, *16*, 1592837. <https://doi.org/10.3389/fimmu.2025.1592837>.
67. Ahn, Y.Y.; Bagrow, J.; Lehmann, S. Link communities reveal multiscale complexity in networks. *Nature* **2010**, *466*, 761–764. <https://doi.org/10.1038/nature09182>.
68. Vendramin, R.; Litchfield, K.; Swanton, C. Cancer evolution: Darwin and beyond. *EMBO J.* **2021**, *40*, EMBJ2021108389.
69. Lock, M. Eclipse of the gene and the return of divination. *Curr. Anthropol.* **2025**, *46*, S47–S70. <https://doi.org/10.1086/432452>.
70. Moore, D.S.; Lickliter, R. Development as explanation: Understanding phenotypic stability and variability after the failure of genetic determinism. *Prog. Biophys. Mol. Biol.* **2023**, *178*, 72–77. <https://doi.org/10.1016/j.pbiomolbio.2023.01.003>.
71. Gibney, E.R.; Nolan, C.M. Epigenetics and gene expression. *Heredity* **2010**, *105*, 4–13. <https://doi.org/10.1038/hdy.2010.54>.
72. Audic, Y.; Hartley, R.S. Post-transcriptional regulation in cancer. *Biol. Cell* **2004**, *96*, 479–498. <https://doi.org/10.1016/j.biocel.2004.05.002>.
73. Müller, M.M. Post-Translational Modifications of Protein Backbones: Unique Functions, Mechanisms, and Challenges. *Biochemistry* **2018**, *57*, 177–185. <https://doi.org/10.1021/acs.biochem.7b00861>.
74. Llovet, J.M.; Castet, F.; Heikenwalder, M.; Maini, M.K.; Mazzaferro, V.; Pinato, D.J.; Pikarsky, E.; Zhu, A.X.; Finn, R.S. Immunotherapies for hepatocellular carcinoma. *Nat. Rev. Clin. Oncol.* **2022**, *19*, 151–172. <https://doi.org/10.1038/s41571-021-00573-2>.
75. Chan, T.A.; Yarchoan, M.; Jaffee, E.; Swanton, C.; Quezada, S.A.; Stenzinger, A.; Peters, S. Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. *Ann. Oncol.* **2019**, *30*, 44–56. <https://doi.org/10.1093/annonc/mdy495>.
76. Dudley, J.C.; Lin, M.T.; Le, D.T.; Eshleman, J.R. Microsatellite instability as a biomarker for PD-1 blockade. *Clin. Cancer Res.* **2016**, *22*, 813–820. <https://doi.org/10.1158/1078-0432.CCR-15-1678>.
77. Chen, C.; Wang, Z.; Ding, Y.; Qin, Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. *Front. Immunol.* **2023**, *14*, 1133308. <https://doi.org/10.3389/fimmu.2023.1133308>.
78. Even Cherev, N. Personalized medicine in practice: Postgenomics from multiplicity to immutability. *Body Soc.* **2020**, *26*, 26–54. <https://doi.org/10.1177/1357034X19886925>.
79. Saad, E.D.; Katz, A.; Buyse, M. Overall survival and post-progression survival in advanced breast cancer: A review of recent randomized clinical trials. *J. Clin. Oncol.* **2010**, *28*, 1958–1962. <https://doi.org/10.1200/JCO.2009.25.5414>.
80. Belin, L.; Tan, A.; De Rycke, Y.; Dechartres, A. Progression-free survival as a surrogate for overall survival in oncology trials: A methodological systematic review. *Br. J. Cancer* **2020**, *122*, 1707–1714. <https://doi.org/10.1038/s41416-020-0805-y>.
81. Mushti, S.L.; Mulkey, F.; Sridhara, R. Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials. *Clin. Cancer Res.* **2018**, *24*, 2268–2275. <https://doi.org/10.1158/1078-0432.CCR-17-1902>.

82. Rothenberg, M.L.; McCarthy, J.; Holmes, P. Price, cost, and value of cancer medicines: A pharmaceutical industry perspective. *Cancer J.* **2020**, *26*, 281–286. <https://doi.org/10.1097/PPO.0000000000000455>.
83. Slomiany, M.; Madhavan, P.; Kuehn, M.; Richardson, S. Value frameworks in oncology: Comparative analysis and implications to the pharmaceutical industry. *Am. Health Drug Benefits* **2017**, *10*, 253. PMID: 28975009; PMCID: PMC5620505.
84. Ho, P.T.C. The Pharma/Biotech Model for Drug Development: Implications for Pediatric Cancer Therapeutics. In *Pediatric Cancer Therapeutics Development Pediatric Oncology*; DiMartino, J., Reaman, G.H., Smith, F.O., Eds.; Springer: Cham, Switzerland, 2022. https://doi.org/10.1007/978-3-031-06357-2_7.
85. Bennett, L.R.; Manderson, L.; Spagnoletti, B. *Cancer and the Politics of Care: Inequalities and Interventions in Global Perspective 2023*; UCL Press: London, UK, 2023; 274p. Available online: <https://library.oapen.org/handle/20.500.12657/61174> (accessed on 30 July 2026).
86. Vega, R.A. *Physicians of the Future: Doctor-Influencers, Patient-Consumers, and the Business of Functional Medicine*; University of Texas Press: Austin, TX, USA, 2024. <https://doi.org/10.1016/j.juro.2013.02.032>.
87. Van Kleunen, L.B. Interpretable Prediction and Decision-Making Under Uncertainty Using Biological Networks. Doctoral Dissertation, University of Colorado at Boulder, Boulder, CO, USA, 2024. Available online: https://scholar.colorado.edu/concern/graduate_thesis_or_dissertations/x346d6230 (accessed on 30 July 2026).
88. Al-Adeem, K.R. Who decides what is publishable? Empirical study on the influence of a journal's editorial board on the observed paradigm shift in US academic accounting research. *N. Am. Account. Stud.* **2019**, *2*, 1–21.
89. Tuttle, B.; Dillard, J. Beyond competition: Institutional isomorphism in US accounting research. *Account. Horiz.* **2007**, *21*, 387–409. <https://doi.org/10.2308/acch.2007.21.4.387>.
90. Pfeffer, J. Barriers to the advance of organizational science: Paradigm development as a dependent variable. *Acad. Manag. Rev.* **1993**, *18*, 599–620. <https://doi.org/10.5465/amr.1993.9402210152>.
91. Soto, A.M.; Sonnenschein, C. Reductionism, organicism, and causality in the biomedical sciences: A critique. In *Perspectives in Biology and Medicine*; Johns Hopkins University Press: Baltimore, MD, USA, 2018; Volume 61, pp. 489–502. <https://doi.org/10.1353/pbm.2018.0059>.
92. Kay, T.; Piekarski, P.K.; Kronauer, D.J. Convergent evolution of a conserved molecular network underlies parenting and sociality. *Nat. Rev. Genet.* **2026**, *27*, 306–322. <https://doi.org/10.1038/s41576-025-00903-5>.
93. Rehan, S.M.; Toth, A.L. Climbing the social ladder: The molecular evolution of sociality. *Trends Ecol. Evol.* **2015**, *30*, 426–433. External Link. <https://doi.org/10.1016/j.tree.2015.05.004>.
94. Makrodimitris, S.; Reinders, M.; van Ham, R. A thorough analysis of the contribution of experimental, derived and sequence-based predicted protein-protein interactions for functional annotation of proteins. *PLoS ONE* **2020**, *15*, e0242723. <https://doi.org/10.1371/journal.pone.0242723>. PMID: 33237964; PMCID: PMC7688180.
95. Peng, J.; Zhao, L. A predicted structural interactome reveals binding interference from intrinsically disordered regions. *PLoS Comput. Biol.* **2026**, *22*, e1013899. <https://doi.org/10.1371/journal.pcbi.1013899>. PMID: 41570036; PMCID: PMC12854418.
96. Lambourne, L.; Yadav, A.; Wang, Y.; Desbuleux, A.; Kim, D.K.; Laval, F.; Spirohn-Fitzgerald, K.; Cafarelli, T.; Pons, C.; Kovács, I.A.; et al. Experimental assessment of AI-based interactome mapping. *Nat. Commun.* **2026**, *17*, 4894. <https://doi.org/10.1038/s41467-026-70942-x>. PMID: 41935050; PMCID: PMC13230783.
97. Thombre, K.R.; Gabhane, V.; Gupta, K.R.; Umekar, M.J. Network pharmacology in the multi-omics era: Uncovering novel therapeutic strategies. *Discov. Chem.* **2026**, *3*, 111. <https://doi.org/10.1007/s44371-026-00567-y>.
98. Solernou, A.; Thiayagalingam, J.; Duta, M.C.; Trefethen, A.E. The effect of topology-aware process and thread placement on performance and energy. In *Supercomputing ISC 2013*; Kunkel, J.M., Ludwig, T., Meuer, H.W., Eds.; Springer: Berlin/Heidelberg, Germany, 2013; Volume 7905, pp. 357–371. https://doi.org/10.1007/978-3-642-38750-0_27.
99. Kuznetsov, N.; Reitmann, V. *Attractor Dimension Estimates for Dynamical Systems: Theory and Computation*; Springer International Publishing AG: Cham, Switzerland, 2020; Volume 38. <https://doi.org/10.1007/978-3-030-50987-3>.
100. Abid, F.; Khan, M.; Shabbir, M. Hallmarks of cancer. In *Nanotheranostics and Precision Oncology, Chapter 2*; Academic Press: Cambridge, MA, USA, 2026; pp. 29–56. <https://doi.org/10.1016/B978-0-443-34671-2.00003-7>. ISBN 978-0-443-34671-2.
101. Mai, Z.; Liu, H. Boolean network-based analysis of the apoptosis network: Irreversible apoptosis and stable surviving. *J. Theor. Biol.* **2009**, *259*, 760–769. <https://doi.org/10.1016/j.jtbi.2009.04.024>.
102. Liu, B.J.; Guan, Y.Y.; Qiao, L.X.; Zhang, J.M.; Li, A.J.; Yang, P.X.; Gao, Y.X.; Chen, D.X.; Wang, C.X.; Wu, J. The mechanism and experimental verification of *Ixeris sonchifolia* promoting apoptosis of hepatocellular carcinoma based on network pharmacology: *Ixeris sonchifolia* Induces Hepatocellular Carcinoma Apoptosis via the PI3K/AKT Pathway. *J. Ethnopharmacol.* **2024**, *327*, 117994. <https://doi.org/10.1016/j.jep.2024.117994>.

103. Zmasek, C.M.; Godzik, A. Evolution of the animal apoptosis network. *Cold Spring Harb. Perspect. Biol.* **2013**, *5*, a008649. <https://doi.org/10.1101/cshperspect.a008649>.
104. Zhang, J.; Tang, Z.; Wang, Y.; Wan, J.; Zhou, Y.; Li, J.; Ming, J. Metabolic Bottlenecks and Opportunities: Reshaping the Tumor Microenvironment for Cancer Immunotherapy. *Cells* **2026**, *15*, 1422. <https://doi.org/10.3390/cells15151422>.
105. Wang, Y.; Ge, M.; Wang, J.; Xu, Y.; Wang, N.; Xu, S. Metabolic reprogramming in ischemic stroke: When glycolytic overdrive meets lipid storm. *Cell Death Dis.* **2025**, *16*, 788. <https://doi.org/10.1038/s41419-025-08114-w>.
106. Sabit, H.; Rashwan, S.; Albrahim, Y.; Wadan, A.-H.S.; Radwan, F.; Alqosaibi, A.I.; Abdel-Ghany, S.; Arneth, B. Targeting Resistance Pathways in Breast Cancer Through Precision Oncology: Nanotechnology and Immune Modulation Approaches. *Biomedicines* **2025**, *13*, 1691. <https://doi.org/10.3390/biomedicines13071691>.
107. Laubenbacher, R.; Mehrad, B.; Shmulevich, I.; Trayanova, N. Digital twins in medicine. *Nat. Comput. Sci.* **2024**, *4*, 184–191. <https://doi.org/10.1038/s43588-024-00607-6>.
108. Li, X.; Loscalzo, J.; Mahmud, A.F.; Aly, D.M.; Rzhetsky, A.; Zitnik, M.; Benson, M. Digital twins as global learning health and disease models for preventive and personalized medicine. *Genome Med.* **2025**, *17*, 11. <https://doi.org/10.1186/s13073-025-01435-7>.
109. Wang, Y.; Wang, T.; Cao, Y.; Qiao, X.; Han, X.; Liu, Z.P. TopMarker: Computational screening biomarkers of hepatocellular carcinoma from transcriptome and interactome based on differential network topological parameters. *Comput. Biol. Chem.* **2024**, *112*, 108166. <https://doi.org/10.1016/j.compbiolchem.2024.108166>.
110. Colonna, G. Effects of SARS-CoV-2 Spike S1 Subunit on the Interplay Between Hepatitis B and Hepatocellular Carcinoma Related Molecular Processes in Human Liver. *Livers* **2024**, *5*, 1. <https://doi.org/10.3390/livers5010001>.
111. Han, Y.; Niu, J.; Wang, D.; Li, Y. Hepatitis C Virus Protein Interaction Network Analysis Based on Hepatocellular Carcinoma. *PLoS ONE* **2016**, *11*, e0153882. <https://doi.org/10.1371/journal.pone.0153882>.
112. Koh, G.C.; Porras, P.; Aranda, B.; Hermjakob, H.; Orchard, S.E. Analyzing Protein–Protein Interaction Networks†. *J. Proteome Res.* **2012**, *11*, 2014–2031. <https://doi.org/10.1021/pr201211w>.
113. Dai, S.; Zhang, Y.; Yu, W.; Li, N. Capturing the Hierarchically Assorted Protein-protein Interaction Modules of Mammalian Cell. *bioRxiv* **2024**, 2024-09. Available online: <https://www.biorxiv.org/content/10.1101/2024.09.30.615776v1.full-text> (accessed on 30 July 2026).
114. Langton, C.G. Computation at the edge of chaos: Phase transitions and emergent computation. *Physica D Nonlinear Phenom.* **1990**, *42*, 12–37. [https://doi.org/10.1016/0167-2789\(90\)90064-V](https://doi.org/10.1016/0167-2789(90)90064-V).
115. Teuscher, C. Revisiting the edge of chaos: Again? *Biosystems* **2022**, *218*, 104693. <https://doi.org/10.1016/j.biosystems.2022.104693>.
116. Mitchell, M.; Crutchfield, J.P.; Hraber, P.T. Dynamics, computation, and the “edge of chaos”: A re-examination. In *Santa Fe Institute Studies in the Science of Complexity-Proceedings Volume, Working Paper 93-06-040*; Addison-Wesley Publishing Co: Reading, MA, USA, 1994; Volume 19, p. 497.
117. Munoz, M.A. Colloquium: Criticality and dynamical scaling in living systems. *Rev. Mod. Phys.* **2018**, *90*, 031001. <https://doi.org/10.1103/RevModPhys.90.031001>.
118. Eliasmith, C. Attractor network. *Scholarpedia* **2007**, *2*, 1380. <https://doi.org/10.4249/scholarpedia.1380>.
119. Kulyk, O. Thermodynamic neural networks and intersection theory: An ontological hypothesis of emergent intelligence. *Cogn. Neurodynamics* **2026**, *20*, 80. <https://doi.org/10.1007/s11571-026-10438-y>.
120. Robledo, A. From Statistical Mechanics to Nonlinear Dynamics and into Complex Systems. *Complexities* **2026**, *2*, 3. <https://doi.org/10.3390/complexities2010003>.
121. Cho, K.-H.; The Researcher Team of Korea Advanced Institute of Science and Technology (KAIST). Reversing Cancer Cells to Normal: Korean Researchers Launch Digital Twin Therapy. 2026. Online Book, AIU, Atlantic International University, Honolulu, USA; AI Virtual Campus of Academic Assignments. Available online: <https://www.aiu.edu/innovative/reversing-cancer-cells-to-normal/> (accessed on 30 July 2026).
122. Waddington, C.H. *The Strategy of the Genes. A Discussion of Some Aspects of Theoretical Biology*; Routledge Library Editions: New York, NY, USA, 2014; ISBN 978-1-138-01731-3.
123. Ferrell, J.E. Bistability, bifurcations, and Waddington’s epigenetic landscape. *Curr. Biol.* **2012**, *22*, R458–R466. <https://doi.org/10.1016/j.cub.2012.03.045>.
124. Amissah, H.A.; Antwi, M.H.; Amissah, T.A.; Combs, S.E.; Shevtsov, M. More than Just Protein Folding: The Epichaperome, Mastermind of the Cancer Cell. *Cells* **2025**, *14*, 204. <https://doi.org/10.3390/cells14030204>. PMID: 39936995; PMCID: PMC11817126.

125. Curtin, P.; Austin, C.; Curtin, A.; Gennings, C.; Figueroa-Romero, C.; Mikhail, K.A.; Botero, T.M.; Goutman, S.A.; Feldman, E.L.; Arora, M. Dysregulated biodynamics in metabolic attractor systems precede the emergence of amyotrophic lateral sclerosis. *PLoS Comput. Biol.* **2020**, *16*, e1007773. <https://doi.org/10.1371/journal.pcbi.1007773>.
126. Biggar, O.; Papadimitriou, C. Sink equilibria and the attractors of learning in games. *arXiv* **2025**, arXiv:2502.07975. <https://doi.org/10.48550/arXiv.2502.07975>.
127. Omar, Y.M.; Plapper, P. A survey of information entropy metrics for complex networks. *Entropy* **2020**, *22*, 1417. <https://doi.org/10.3390/e22121417>.
128. Corning, P.A.; Kline, S.J. Thermodynamics, information and life revisited, Part I: 'To be or entropy'. *Syst. Res. Behav. Sci. Off. J. Int. Fed. Syst. Res.* **1998**, *15*, 273–295. [https://doi.org/10.1002/\(SICI\)1099-1743\(199807/08\)15:4<273::AID-SRES200>3.0.CO;2-B](https://doi.org/10.1002/(SICI)1099-1743(199807/08)15:4<273::AID-SRES200>3.0.CO;2-B).
129. Corning, P.A.; Kline, S.J. Thermodynamics, information and life revisited, Part II: 'Thermoeconomics' and 'control information'. *Syst. Res. Behav. Sci. Off. J. Int. Fed. Syst. Res.* **1998**, *15*, 453–482. [https://doi.org/10.1002/\(SICI\)1099-1743\(199811/12\)15:6<453::AID-SRES201>3.0.CO;2-U](https://doi.org/10.1002/(SICI)1099-1743(199811/12)15:6<453::AID-SRES201>3.0.CO;2-U).
130. Oruganti, G.S. Bridging Quantum Thermodynamics, Gauge Theories, and Quantum Simulations. Doctoral Dissertation, University of Maryland, College Park, MD, USA, 2026.
131. Available online: <https://www.proquest.com/openview/e1d92473a6342ed11853ed9279fc0a47/1?pq-origsite=gscholar&cbl=18750&diss=y> (accessed on 30 July 2026).
132. Tsallis, C. Beyond Boltzmann–Gibbs–Shannon in physics and elsewhere. *Entropy* **2019**, *21*, 696. <https://doi.org/10.3390/e21070696>.
133. Wagner, A. From bit to it: How a complex metabolic network transforms information into living matter. *BMC Syst. Biol.* **2007**, *1*, 33. <https://doi.org/10.1186/1752-0509-1-33>.
134. Zhao, Z.W.; Li, W.Y.; Li, W.Z.; Wang, Y. Syndrome attractors: Providing a system dynamics view of disease from the integrative medicine perspective. *J. Integr. Med.* **2026**, *24*, 287–294. <https://doi.org/10.1016/j.joim.2026.02.001>.
135. Grunt, T.W. Understanding cancer from a biophysical, developmental and systems biology perspective using the landscapes-attractor model. *BioSystems* **2025**, *247*, 105376. <https://doi.org/10.1016/j.biosystems.2024.105376>.
136. Yuan, R.; Zhu, X.; Wang, G.; Li, S.; Ao, P. Cancer as robust intrinsic state shaped by evolution: A key issues review. *Rep. Prog. Phys.* **2017**, *80*, 042701. <https://doi.org/10.1088/1361-6633/aa538e>.
137. Uthamacumaran, A. Histone H3K4/H3K9 Methylation Dynamics Gate Cell Fate Plasticity In Pediatric High-Grade Gliomas: A Systems-Level Attractor Reconstruction. *J. Comput. Biophys. Chem.* **2026**, *26*, 1–36. <https://doi.org/10.1142/S2737416526500481>.
138. Caire, R.; Bordo, R.; Zanonato, F.; Panciera, T.; Audoux, E.; Contessotto, P.; Fakiola, M.; Bason, R.; Romano, O.; Suli, A.; et al. A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer. *Cell* **2026**, *189*, 3701–3718. <https://doi.org/10.1016/j.cell.2026.03.009>.
139. Stubbins, R.J.; Karsan, A. Differentiation therapy for myeloid malignancies: Beyond cytotoxicity. *Blood Cancer J.* **2021**, *11*, 193. <https://doi.org/10.1038/s41408-021-00584-3>.
140. Ginsberg, S.D.; Sharma, S.; Norton, L.; Chiosis, G. Targeting stressor-induced dysfunctions in protein–protein interaction networks via epichaperomes. *Trends Pharmacol. Sci.* **2023**, *44*, 20–33. <https://doi.org/10.1016/j.tips.2022.10.006>.
141. Chude-Okonkwo, U.A.; Malekian, R.; Maharaj, B.T.; Vasilakos, A.V. Molecular communication and nanonetwork for targeted drug delivery: A survey. *IEEE Commun. Surv. Tutor.* **2017**, *19*, 3046–3096. <https://doi.org/10.1109/COMST.2017.2705740>.
142. Marconi, M.; Alfaro-Bittner, K.; Sarrazin, L.; Giudici, M.; Tredicce, J. Critical slowing down in a real physical system. *Chaos Solitons Fractals* **2024**, *186*, 115218. <https://doi.org/10.1016/j.chaos.2024.115218>.
143. Sheu, J.-C.; Sung, J.-L.; Chen, D.-S.; Yang, P.-M.; Lai, M.-Y.; Lee, C.-S.; Hsu, H.-C.; Chuang, C.-N.; Yang, P.-C.; Wang, T.-H.; et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. *Gastroenterology* **1985**, *89*, 259–266. [https://doi.org/10.1016/0016-5085\(85\)90324-5](https://doi.org/10.1016/0016-5085(85)90324-5).
144. Kim, Y.; Powathil, G.; Kang, H.; Trucu, D.; Kim, H.; Lawler, S.; Chaplain, M. Strategies of Eradicating Glioma Cells: A Multi-Scale Mathematical Model with MiR-451-AMPK-mTOR Control. *PLoS ONE* **2015**, *10*, e0114370. <https://doi.org/10.1371/journal.pone.0114370>.
145. Hinrichsen, H. Non-equilibrium phase transitions. *Physica A Stat. Mech. Its Appl.* **2006**, *369*, 1–28. <https://doi.org/10.1016/j.physa.2006.04.007>.
146. Salman, H.; Biswas, K.; Brenner, N. Emergent homeostasis and degeneracy from multi-dimensional attractors. *bioRxiv* **2025**. <https://doi.org/10.1101/2025.05.07.652484>.
147. Scheffer, M.; Carpenter, S.R.; Lenton, T.M.; Bascompte, J.; Brock, W.; Dakos, V.; Van De Coppel, J.; Van De Leemput, I.A.; Levin, S.A.; Van Nes, E.G.; et al. Anticipating critical transitions. *Science* **2012**, *338*, 344–348. <https://doi.org/10.1126/science.1225244>.

148. Lewin, R. *Complexity: Life at the Edge of Chaos*, 2nd ed.; The University of Chicago Press: Chicago, IL, USA, 1999. ISBN 0-226-47654-5.
149. Tompa, P.; Rose, G.D. The Levinthal paradox of the interactome. *Protein Sci.* **2011**, *20*, 2074–2079. <https://doi.org/10.1002/pro.747>. PMID: 21987416; PMCID: PMC3302650.
150. Ilan, Y. The Constrained Disorder Principle: A Paradigm Shift for Accurate Interactome Mapping and Information Analysis in Complex Biological Systems. *Bioengineering* **2025**, *12*, 1255. <https://doi.org/10.3390/bioengineering12111255>.
151. Choudhary, D.; Foster, K.R.; Uphoff, S. Chaos in a bacterial stress response. *Curr. Biol.* **2023**, *33*, 5404–5414. <https://doi.org/10.1016/j.cub.2023.11.002>.
152. Koverda, V.P.; Skokov, V.N. Noise-induced chaos and 1/f power spectrum at nonequilibrium phase transitions. *Physica A Stat. Mech. Its Appl.* **2022**, *587*, 126509. <https://doi.org/10.1016/j.physa.2021.126509>.
153. Kuehn, C. A mathematical framework for critical transitions: Normal forms, variance and applications. *J. Nonlinear Sci.* **2013**, *23*, 457–510. <https://doi.org/10.1007/s00332-012-9158-x>.
154. Heltberg, M.L.; Krishna, S.; Jensen, M.H. On chaotic dynamics in transcription factors and the associated effects in differential gene regulation. *Nat. Commun.* **2019**, *10*, 71. <https://doi.org/10.1038/s41467-018-07932-1>.
155. Zhang, J.; Chen, H.; Li, R.; Taft, D.A.; Yao, G.; Bai, F.; Xing, J. Spatial clustering and common regulatory elements correlate with coordinated gene expression. *PLoS Comput. Biol.* **2019**, *15*, e1006786. <https://doi.org/10.1371/journal.pcbi.1006786>.
156. Vasconcelos, A.G.; Danaher, P.; McGuire, D.; Wakefield, J.; Shojaie, A. Accounting for spatial correlation in graphical analysis of spatial transcriptomics data. *bioRxiv* **2025**, 2025–2107. <https://doi.org/10.1101/2025.07.23.666450>.
157. Asfa, S.S.; Arshinchi Bonab, R.; Önder, O.; Uça Apaydın, M.; Döşeme, H.; Küçük, C.; Georgakilas, A.G.; Stadler, B.M.; Logotheti, S.; Kale, S.; et al. Computer-Aided Identification and Design of Ligands for Multi-Targeting Inhibition of a Molecular Acute Myeloid Leukemia Network. *Cancers* **2024**, *16*, 3607. <https://doi.org/10.3390/cancers16213607>.
158. Huang, S.; Kauffman, S. How to escape the cancer attractor: Rationale and limitations of multi-target drugs. In *Seminars in Cancer Biology*; Academic Press: Cambridge, MA, USA, 2013; Volume 23, pp. 270–278. <https://doi.org/10.1016/j.semcancer.2013.06.003>.
159. Tolman, R.C.; Fine, P.C. On the irreversible production of entropy. *Rev. Mod. Phys.* **1948**, *20*, 51. <https://doi.org/10.1103/RevModPhys.20.51>.
160. Plumber, S.A.; Tate, T.; Al-Ahmadie, H.; Chen, X.; Choi, W.; Basar, M.; Lu, C.; Viny, A.; Batourina, E.; Li, J.; et al. Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer. *Nat. Commun.* **2025**, *15*, 6538. <https://doi.org/10.1038/s41467-024-50678-2>.
161. Ishay-Ronen, D.; Christofori, G. Targeting cancer cell metastasis by converting cancer cells into fat. *Cancer Res.* **2019**, *79*, 5471–5475. <https://doi.org/10.1158/0008-5472.CAN-19-1242>.
162. Rousselot, P.; Prost, S.; Guilhot, J.; Roy, L.; Etienne, G.; Legros, L.; Charbonnier, A.; Coiteux, V.; Cony-Makhoul, P.; Huguet, F.; et al. Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study. *Cancer* **2017**, *123*, 1791–1799. <https://doi.org/10.1002/cncr.30490>.
163. Prost, S.; Relouzat, F.; Spentchian, M.; Ouzegdouh, Y.; Saliba, J.; Massonnet, G.; Beressi, J.P.; Verhoeyen, E.; Raggueneau, V.; Maneglier, B.; et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR γ agonists. *Nature* **2015**, *525*, 380–383. <https://doi.org/10.1038/nature15248>.
164. Hendrix, M.J.C.; Seftor, E.A.; Seftor, R.E.B.; Kasemeier-Kulesa, J.; Kulesa, P.M.; Postovit, L.M. Reprogramming metastatic tumour cells with embryonic microenvironments. *Nat. Rev. Cancer* **2007**, *7*, 246–255. <https://doi.org/10.1038/nrc2108>.
165. Stadhouders, R.; Vidal, E.; Serra, F.; Di Stefano, B.; Le Dily, F.; Quilez, J.; Gomez, A.; Collombet, S.; Berenguer, C.; Cuartero, Y.; et al. Transcription factors orchestrate dynamic interplay between genome topology and gene regulation during cell reprogramming. *Nat. Genet.* **2018**, *50*, 238–249. <https://doi.org/10.1038/s41588-017-0030-7>.
166. Zhang, O.; Lin, H.; Zhang, X.; Wang, X.; Wu, Z.; Ye, Q.; Zhao, W.; Wang, J.; Ying, K.; Kang, Y.; et al. Graph neural networks in modern AI-aided drug discovery. *Chem. Rev.* **2025**, *125*, 10001–10103.
167. Bergers, G.; Fendt, S.M. The metabolism of cancer cells during metastasis. *Nat. Rev. Cancer* **2021**, *21*, 162–180. <https://doi.org/10.1038/s41568-020-00320-2>.
168. Tzeng, Y.D.T.; Raj, E.N.; Cheng, S.H.; Yong, S.B.; Lin, S.C.; Peng, R.W.; Li, C.J. Tumor metabolic plasticity in therapy resistance: From the Warburg effect to mitochondrial hijacking. *Theranostics* **2026**, *16*, 4865–4882. <https://doi.org/10.7150/thno.131708>.
169. Madala, H.R.; Helenius, I.T.; Zhou, W.; Mills, E.; Zhang, Y.; Liu, Y.; Metelo, A.M.; Kelley, M.L.; Punganuru, S.; Kim, K.B.; et al. Nitrogen trapping as a therapeutic strategy in tumors with mitochondrial dysfunction. *Cancer Res.* **2020**, *80*, 3492–3506. <https://doi.org/10.1158/0008-5472.CAN-20-0246>.

170. Shi, J.; Han, W.; Wang, J.; Kong, X. Anti-Tumor strategies targeting nutritional deprivation: Challenges and opportunities. *Adv. Mater.* **2025**, *37*, 2415550. <https://doi.org/10.1002/adma.202415550>.
171. Nakagawa, T.; Lomb, D.J.; Haigis, M.C.; Guarente, L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. *Cell* **2009**, *137*, 560–570. <https://doi.org/10.1016/j.cell.2009.02.026>.
172. Lee, J.S.; Kang, J.H.; Lee, S.H.; Hong, D.; Son, J.; Hong, K.M.; Song, J.; Kim, S.Y. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC. *Cell Death Dis.* **2016**, *7*, e2511. <https://doi.org/10.1038/cddis.2016.404>.
173. Du, X.; Wang, Y.; Huang, J.; Vigder, N.; Jin, T.; Liu, Z.; Hua, W.; Li, W.; Li, F. Targeting glutamine catabolism suppresses eosinophil expansion and activation to alleviate allergic airway inflammation. *Biochem. Pharmacol.* **2025**, *242*, 117443. <https://doi.org/10.1016/j.bcp.2025.117443>.
174. Węglarz-Tomczak, E.; Mondeel, T.D.; Piebes, D.G.; Westerhoff, H.V. Nature and Nurture integrated through an adjustable Flux Balance Analysis: The impact of cell-nutrition changes on the Warburg effect in hepatocellular carcinoma. *bioRxiv* **2019**, 674150. <https://doi.org/10.1101/674150>.
175. Yu, C.; Neumann, S.; Pattison, S.; Wang, J. Global Quantitative Dynamics and Early Warning Signals of Hepatocellular Carcinoma: Integrating Theoretical Modeling with Experimental Validation. *J. Phys. Chem. B* **2026**, *130*, 2771–2781. <https://doi.org/10.1021/acs.jpcc.6c00322>.
176. Li, H.; Qian, L.; Ji, Y.; Geng, Y.; Lu, Y.; Zhang, L.; Xu, Y.; Zong, W.; Jiang, X.; Zhou, X.; et al. B-catenin mutation reprograms ketone body metabolism to drive hepatocellular carcinoma metastasis and resistance to ketogenic therapy via transcriptional activation of OXCT1. *Cell Death Dis.* **2026**, *17*, 301. <https://doi.org/10.1038/s41419-026-08457-y>.
177. Kimura, N.; Kitajima, Y.; Higure, K.; Matsufuji, S.; Ikeda, S.; Furukawa, S.; Yukimoto, K.; Tanaka, T.; Noshiro, H. Putative Role of Fatty Acid Metabolic Therapy Using Ketogenic Diet and HIF-1 α Inhibition in Hepatocellular Carcinoma: Evidence from an In Vitro Study. *Int. J. Mol. Sci.* **2025**, *26*, 11769. <https://doi.org/10.3390/ijms262411769>.
178. Lo, E.K.K.; Felicianna; Xu, J.-H.; Zhan, Q.; Zeng, Z.; El-Nezami, H. The Emerging Role of Branched-Chain Amino Acids in Liver Diseases. *Biomedicines* **2022**, *10*, 1444. <https://doi.org/10.3390/biomedicines10061444>.
179. Braunstein, A.; Dall'Asta, L.; Semerjian, G.; Zdeborová, L. Network dismantling. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 12368–12373. <https://doi.org/10.1073/pnas.1605083113>. PMID: 27791075; PMCID: PMC5098660.
180. Boltz, T.A.; Devkota, P.; Wuchty, S. Collective influencers in protein interaction networks. *Sci. Rep.* **2019**, *9*, 3948. <https://doi.org/10.1038/s41598-019-40410-2>. PMID: 30850642; PMCID: PMC6408499.
181. Módos, D.; Bulusu, K.C.; Fazekas, D.; Kubisch, J.; Brooks, J.; Marczell, I.; Szabo, P.M.; Vellai, T.; Csermely, P.; Lenti, K.; et al. Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anti-cancer therapies. *npj Syst. Biol. Appl.* **2017**, *3*, 2. <https://doi.org/10.1038/s41540-017-0003-6>.
182. Pavlopoulos, G.A.; Secrier, M.; Moschopoulos, C.N.; Soldatos, T.G.; Kossida, S.; Aerts, J.; Schneider, R.; Bagos, P.G. Using graph theory to analyze biological networks. *BioData Min.* **2011**, *4*, 10. <https://doi.org/10.1186/1756-0381-4-10>. PMID: 21527005; PMCID: PMC3101653.
183. Dimitrakopoulos, C.M.; Beerenwinkel, N. Computational approaches for the identification of cancer genes and pathways. *Wiley Interdiscip. Rev. Syst. Biol. Med.* **2017**, *9*, e1364. <https://doi.org/10.1002/wsbm.1364>.
184. Sardina, D.; Micale, G.; Ferro, A.; Pulvirenti, A.; Giugno, R. INBIA: A boosting methodology for proteomic network inference. *BMC Bioinform.* **2018**, *19*, 188. <https://doi.org/10.1186/s12859-018-2183-5>.
185. Rai, A.; Pradhan, P.; Nagraj, J.; Lohitesh, K.; Chowdhury, R.; Jalan, S. Understanding cancer complexome using networks, spectral graph theory and multilayer framework. *Sci. Rep.* **2017**, *7*, 41676. <https://doi.org/10.1038/srep41676>.
186. Pe'er, D.; Hachohen, N. Principles and strategies for developing network models in cancer. *Cell* **2011**, *144*, 864–873. <https://doi.org/10.1016/j.cell.2011.03.001>. PMID: 21414479; PMCID: PMC3082135.
187. Sun, P.G.; Quan, Y.N.; Miao, Q.G.; Chi, J. Identifying influential genes in protein–protein interaction networks. *Inf. Sci.* **2018**, *454*, 229–241. <https://doi.org/10.1016/j.ins.2018.04.078>.
188. Ren, X.L.; Gleinig, N.; Helbing, D.; Antulov-Fantulin, N. Generalized network dismantling. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 6554–6559. <https://doi.org/10.1073/pnas.1806108116>.
189. Liu, X.; Hu, J.; Wang, Y.; Liu, Y.Y.; Zhang, H.T. Optimal dismantling of directed networks. *Nat. Commun.* **2026**, *17*, 7866. <https://doi.org/10.1038/s41467-026-74467-1>. PMID: 42331845; PMCID: PMC13442883.
190. Wu, M.; Dai, B.; Shi, W.; Mou, J.; Tan, S.; Boccaletti, S.; Lu, X. Network dismantling with community-based edge percolation. *Inf. Process. Manag.* **2026**, *63*, 104295. <https://doi.org/10.1016/j.ipm.2025.104295>.

191. Bannaga, A.S. Exploration of Urine and Plasma Biomarkers in Liver Fibrosis and Hepatocellular Carcinoma. Doctoral Dissertation, University of Warwick, Coventry, UK, 2021. Available online: <https://wrap.warwick.ac.uk/id/eprint/163705/#1> (accessed on 30 July 2026).
192. Proverbio, D.; Skupin, A.; Gonçalves, J. Systematic analysis and optimization of early warning signals for critical transitions using distribution data. *iScience* **2023**, *26*, 107156. <https://doi.org/10.1016/j.isci.2023.107156>.
193. Rawding, P. Engineered Peptides and Functionalized Polymeric Nanoparticles for Targeted Cancer Immunotherapy. Doctoral Dissertation, The University of Wisconsin-Madison, Madison, WI, USA, 2024. Available online: <https://www.proquest.com/openview/7639a7a05c6427f72ae6b6079aec5db6/1?cbl=18750&diss=y&pq-origsite=gscholar> (accessed on 19 May 2026).
194. Di Marco, T.; Vergaro, D.; Greco, A. COPZ1: An example of non-oncogene addiction in human tumors. *Front. Pharmacol.* **2025**, *16*, 1636326. <https://doi.org/10.3389/fphar.2025.1636326>.
195. Ye, Y.; Yu, B.; Wang, H.; Yi, F. Glutamine metabolic reprogramming in hepato-cellular carcinoma. *Front. Mol. Biosci.* **2023**, *10*, 1242059. <https://doi.org/10.3389/fmolb.2023.1242059>.
196. Wu, Y.; Wong, C.C.L. Targeting amino acid metabolism in hepatocellular carcinoma. *Trends Mol. Med.* **2026**. <https://doi.org/10.1016/j.molmed.2026.06.002>.
197. Beier, A.M.K. Therapeutic potential of antiandrogens and targeting glutamine metabolism in prostate cancer. In *TUD_The Collaborative University*; Technische Universität Dresden: Dresden, Germany, 2025. Available online: <https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-1001117> (accessed on 30 July 2026).
198. Issa, L.H.B.; Fléchon, L.; Laine, W.; Ouelkdite, A.; Gaggero, S.; Cozzani, A.; Tilmont, R.; Chauvet, P.; Gower, N.; Sklavenitis-Pistofidis, R.; et al. MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma. *iScience* **2024**, *27*, 109417. <https://doi.org/10.1016/j.isci.2024.109417>.
199. Zhang, X.; Zhang, W. From Cancer Drivers to Cancer Keepers: Paradigm Shift and Clinical Implications. *arXiv* **2025**, arXiv:2508.16128. <https://doi.org/10.48550/arXiv.2508.16128>.
200. Jia, D.; Jolly, M.K.; Kulkarni, P.; Levine, H. Phenotypic plasticity and cell fate decisions in cancer: Insights from dynamical systems theory. *Cancers* **2017**, *9*, 70. <https://doi.org/10.3390/cancers9070070>.
201. Bermúdez-Guzmán, L. Pan-cancer analysis of non-oncogene addiction to DNA repair. *Sci. Rep.* **2021**, *11*, 23264. <https://doi.org/10.1038/s41598-021-02773-3>.
202. Huang, S.; Ingber, D.E. A non-genetic basis for tumorigenesis and metastatic progression: Self-organizing attractors in cell regulatory networks. *Breast Dis.* **2026**. Available online: https://www.researchgate.net/profile/Sui-Huang-7/publication/264877785_A_non-genetic_basis_for_tumorigenesis_and_metastatic_progression_self-organizing_attractors_in_cell_regulatory_networks/links/541491080cf2fa878ad3ea2c/A-non-genetic-basis-for-tumorigenesis-and-metastatic-progression-self-organizing-attractors-in-cell-regulatory-networks.pdf (accessed on 30 July 2026).
203. Uthamacumaran, A. *Chaos and Complexity: Hallmarks of Cancer Progression*. *Cancer Systems Biology: Translational Mathematical Oncology*; Salgia, R., Jolly, M.K., Kulkarni, P., Rangarajan, G., Eds.; Oxford University Press: Oxford, UK, 2026; Section 9, 413p. <https://doi.org/10.1093/med/9780192867636.001.0001>. ISBN 978-0-19-286763-6.
204. Hjaltelin, J.X.; Izarzugaza, J.M.; Jensen, L.J.; Russo, F.; Westergaard, D.; Brunak, S. Identification of hyper-rewired genomic stress non-oncogene addiction genes across 15 cancer types. *npj Syst. Biol. Appl.* **2019**, *5*, 27. <https://doi.org/10.1038/s41540-019-0104-5>.
205. Chang, Z.; Guo, X.; Li, X.; Wang, Y.; Zang, Z.; Pei, S.; Lu, W.; Li, Y.; Huang, J.D.; Xiao, Y.; et al. Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization. *Cell* **2025**, *188*, 1842–1857.e20. <https://doi.org/10.1016/j.cell.2025.02.002>.
206. Wang, H.; Arulraj, T.; Ippolito, A.; Popel, A.S. Quantitative Systems Pharmacology Modeling in Immuno-Oncology: Hypothesis Testing, Dose Optimization, and Efficacy Prediction. *Handb. Exp. Pharmacol.* **2025**, *289*, 261–284. https://doi.org/10.1007/164_2024_735.
207. Rocca, A.; Kholodenko, B.N. Can Systems Biology Advance Clinical Precision Oncology? *Cancers* **2020**, *13*, 6312. <https://doi.org/10.3390/cancers13246312>.
208. Anand, R.; Sarmah, D.T.; Chatterjee, S. Extracting proteins involved in disease progression using temporally connected networks. *BMC Syst. Biol.* **2018**, *12*, 78. <https://doi.org/10.1186/s12918-018-0600-z>.
209. Morone, F.; Makse, H. Influence maximization in complex networks through optimal percolation. *Nature* **2015**, *524*, 65–68. <https://doi.org/10.1038/nature14604>.

210. Kasapoğlu, F.Ü. Cancer Driver Subnetwork Identification by Network Dismantling Methods. Master's Thesis, Middle East Technical University: Ankara, Turkey, 2021. Available online: <https://www.proquest.com/openview/3c91316b9e907ff2f3da48e3f29c819b/1?pq-riqsite=gscholar&cbl=2026366&diss=y> (accessed on 30 July 2026).
211. Pu, T.; Zeng, L.; Chen, C. Deep Reinforcement Learning for Network Dismantling: A K-Core Based Approach. *Mathematics* **2024**, *12*, 1215. <https://doi.org/10.3390/math12081215>.
212. Wandelt, S.; Sun, X.; Feng, D.; Zanin, M.; Havlin, S. A comparative analysis of approaches to network-dismantling. *Sci. Rep.* **2018**, *8*, 13513. <https://doi.org/10.1038/s41598-018-31902-8>.
213. Shin, D.; Lee, J.; Gong, J.R.; Cho, K.H. Percolation transition of cooperative mutational effects in colorectal tumorigenesis. *Nat. Commun.* **2017**, *8*, 1270. <https://doi.org/10.1038/s41467-017-01171-6>. PMID: 29097710; PMCID: PMC5668266.
214. Gibbs, D.L.; Shmulevich, I. Solving the influence maximization problem reveals regulatory organization of the yeast cell cycle. *PLoS Comput. Biol.* **2017**, *13*, e1005591. <https://doi.org/10.1371/journal.pcbi.1005591>.
215. Rodrigues, J.A. Stochastic Graph-Based Models of Tumor Growth and Cellular Interactions. *Appl. Math.* **2025**, *5*, 62. <https://doi.org/10.3390/appliedmath5020062>.
216. Shante, V.K.; Kirkpatrick, S. An introduction to percolation theory. *Adv. Phys.* **1971**, *20*, 325–357. <https://doi.org/10.1080/00018737100101261>.
217. Zdeborová, L.; Zhang, P.; Zhou, H.J. Fast and simple decycling and dismantling of networks. *Sci. Rep.* **2016**, *6*, 37954. <https://doi.org/10.1038/srep37954>.
218. Morone, F.; Min, B.; Bo, L.; Mari, R.; Makse, H.A. Collective Influence Algorithm to find influencers via optimal percolation in massively large social media. *Sci. Rep.* **2016**, *6*, 30062. <https://doi.org/10.1038/srep30062>. PMID: 27455878; PMCID: PMC4960527.
219. Engsig, M.; Tejedor, A.; Moreno, Y.; Foufoula-Georgiou, E.; Kasmi, C. DomRank Centrality reveals structural fragility of complex networks via node dominance. *Nat. Commun.* **2024**, *15*, 56. <https://doi.org/10.1038/s41467-023-44257-0>. PMID: 38167342; PMCID: PMC10761873.
220. Gubarkova, E.V.; Sovetsky, A.A.; Vorontsov, D.A.; Buday, P.A.; Sirotkina, M.A.; Plekhanov, A.A.; Kuznetsov, S.S.; Matveyev, A.L.; Matveev, L.A.; Gamayunov, S.V.; et al. Compression optical coherence elastography versus strain ultrasound elastography for breast cancer detection and differentiation: Pilot study. *Biomed. Opt. Express* **2022**, *13*, 2859–2880. <https://doi.org/10.1364/BOE.451059>.
221. Luo, X.; He, X.; Zhang, X.; Zhao, X.; Zhang, Y.; Shi, Y.; Hua, S. Hepatocellular carcinoma: Signaling pathways, targeted therapy, and immunotherapy. *MedComm* **2024**, *5*, e474. <https://doi.org/10.1002/mco2.474>.
222. Ng, C.K.Y.; Dazert, E.; Boldanova, T.; Coto-Llerena, M.; Nuciforo, S.; Ercan, C.; Suslov, A.; Meier, M.A.; Bock, T.; Schmidt, A.; et al. Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages. *Nat. Commun.* **2022**, *13*, 2436. <https://doi.org/10.1038/s41467-022-29960-8>.
223. Rahmani, A.H.; Beg, A.; Sarwar, T.; Khan, A.A. Uncovering Prognostic Biomarkers Underlying Hepatocellular Carcinoma Through Integrative Multi-Omics and a Network-Based Approach. *Int. J. Mol. Sci.* **2026**, *27*, 4164. <https://doi.org/10.3390/ijms27104164>.
224. Zhen, C.; Zhu, C.; Chen, H.; Xiong, Y.; Tan, J.; Chen, D.; Li, J. Systematic analysis of molecular mechanisms for HCC metastasis via text mining approach. *Oncotarget* **2017**, *8*, 13909–13916. <https://doi.org/10.18632/oncotarget.14692>. PMID: 28108733; PMCID: PMC5355149.
225. Xing, X.; Hu, E.; Ouyang, J.; Zhong, X.; Wang, F.; Liu, K.; Wang, L.Y.; Chen, G.; Li, Z.; Wu, L.; et al. Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy. *Cell Rep. Med.* **2023**, *4*, 101315. <https://doi.org/10.1016/j.xcrm.2023.101315>.
226. Zou, X.; Wang, Y.; Luan, M.; Zhang, Y. Multi-omics and single-cell approaches reveal molecular subtypes and key cell interactions in hepatocellular carcinoma. *Front. Pharmacol.* **2025**, *16*, 1605162. <https://doi.org/10.3389/fphar.2025.1605162>.
227. Goossens, N.; Sun, X.; Hoshida, Y. Molecular classification of hepatocellular carcinoma: Potential therapeutic implications. *Hepat. Oncol.* **2015**, *2*, 371–379. <https://doi.org/10.2217/hep.15.26>. PMID: 26617981; PMCID: PMC4662420.
228. Deng, Q.; Huang, Y.; Zeng, J.; Li, X.; Zheng, X.; Guo, L.; Shi, J.; Bai, L. Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials. *Biomed. Pharmacother.* **2024**, *179*, 117343. <https://doi.org/10.1016/j.biopha.2024.117343>.
229. Gottumukkala, S.B.; Malaieaswaran, A.; Palanisamy, A. Comprehensive Network of Signaling Pathways in Hepatocellular Carcinoma and Network Analysis Reveals PTK2, GSK3 β , and β -catenin to be Crucial for Cancer Progression. *bioRxiv* **2025**. <https://doi.org/10.1101/2025.07.25.666714>.

230. Wang, B.; Huang, C.; Liu, X.; Liu, Z.; Zhang, Y.; Zhao, W.; Xu, Q.; Ho, P.C.; Xiao, Z. IMetAct: An integrated systematic inference of metabolic activity for dissecting tumor metabolic preference and tumor-immune microenvironment. *Cell Rep.* **2025**, *44*, 115375. <https://doi.org/10.1016/j.celrep.2025.115375>.
231. Aoki, T.; Nishida, N.; Kurebayashi, Y.; Sakai, K.; Fujiwara, N.; Tsurusaki, M.; Hanaoka, K.; Morita, M.; Chishina, H.; Takita, M.; et al. Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway. *Clin. Mol. Hepatol.* **2025**, *31*, 981. <https://doi.org/10.3350/cmh.2024.1088>.
232. Zhang, N.; Tian, X.; Liu, F.; Jin, X.; Zhang, J.; Hao, L.; Jiang, S.; Liu, Q. Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: Insights from network pharmacology, molecular docking, and experimental validation. *Front. Pharmacol.* **2025**, *16*, 1514997. <https://doi.org/10.3389/fphar.2025.1514997>.
233. Fillinger, L.; Walter, S.; Ley, M.; Kęska-Izwsowska, K.; Dehkordi, L.G.; Kratochwill, K.; Perco, P. Computational modeling approaches and regulatory pathways for drug combinations. *Drug Discovery Today* **2025**, *30*, 104345. <https://doi.org/10.1016/j.drudis.2025.104345>.
234. Juanes-Gusano, D.; Fernández-Roldán, B.; Coveñas, R.; Hijazi, M. Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood–Brain Barrier Dynamics and Combinatorial Translational Strategies. *Int. J. Mol. Sci.* **2026**, *27*, 6590. <https://doi.org/10.3390/ijms27156590>.
235. Fulgenzi, C.A.M.; Cheon, J.; D'Alessio, A.; Nishida, N.; Ang, C.; Marron, T.U.; Wu, L.; Saeed, A.; Wietharn, B.; Cammarota, A.; et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. *Eur. J. Cancer* **2022**, *175*, 204–213. <https://doi.org/10.1016/j.ejca.2022.08.024>.
236. Selvaggio, G.; Chaouiya, C.; Janody, F. In Silico Logical Modelling to Uncover Cooperative Interactions in Cancer. *Int. J. Mol. Sci.* **2021**, *22*, 4897. <https://doi.org/10.3390/ijms22094897>.
237. Bloomingdale, P.; Nguyen, V.A.; Niu, J.; Mager, D.E. Boolean network modeling in systems pharmacology. *J. Pharmacokinet. Pharmacodyn.* **2018**, *45*, 159–180. <https://doi.org/10.1007/s10928-017-9567-4>.
238. Fumiã, H.F.; Martins, M.L. Boolean Network Model for Cancer Pathways: Predicting Carcinogenesis and Targeted Therapy Outcomes. *PLoS ONE* **2013**, *8*, e69008. <https://doi.org/10.1371/journal.pone.0069008>.
239. Chakkerla, M.; Annapureddy, S.R.; Vaddi, S.R.; Rampurawala, I.M.; Rajitha, B. Targeted signaling pathways in liver cancer: Current insights and future directions. In *Targeting DNA Repair Mechanisms, Tumor Genetics, and Signaling Pathways*; Nagaraju, G.P., Bassel, F.E.-R., Eds.; Academic Press: Cambridge, MA, USA, 2026; Chapter 7, pp. 97–118. <https://doi.org/10.1016/B978-0-443-43976-6.00002-8>.
240. Zaman, S.N.; Johnson, P.J.; Williams, R. Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. *Cancer* **1990**, *65*, 1607–1610. [https://doi.org/10.1002/1097-0142\(19900401\)65:7<1607::AID-CNCR2820650726>3.0.CO;2-2](https://doi.org/10.1002/1097-0142(19900401)65:7<1607::AID-CNCR2820650726>3.0.CO;2-2).
241. Zhu, X.; Chen, Z.; Ge, M.W.; Rehman, A.U.; Chen, H.L.; Zhu, H.; Zheng, B. Spatiotemporal patterns and clustering of prostate cancer incidence in China: A Bayesian modeling study of cancer registry data. *BMC Public Health* **2026**, *26*, 973. <https://doi.org/10.1186/s12889-026-26619-7>.
242. Heaster, T.M.; Landman, B.A.; Skala, M.C. Quantitative spatial analysis of metabolic heterogeneity across in vivo and in vitro tumor models. *Front. Oncol.* **2019**, *9*, 472785. <https://doi.org/10.3389/fonc.2019.01144>.
243. Vlad, I.T.; Juan, P.; Mateu, J. Bayesian spatio-temporal prediction of cancer dynamics. *Comput. Math. Appl.* **2015**, *70*, 857–868. <https://doi.org/10.1016/j.camwa.2015.06.006>.
244. Zhang, X.; Zhang, D.; Zhang, Y.; Wang, J.; Lu, J. Restoration of skeletal muscle function via mesenchymal stem cells: Mechanistic insights and therapeutic advances in myasthenia gravis. *Front. Cell Dev. Biol.* **2025**, *13*, 1658062. <https://doi.org/10.3389/fcell.2025.1658062>.
245. Rashidi, M.; Mousavi, V.; Perera, S.; Devitt, J. Bridge health monitoring through photogrammetry-based digital twins: A topological data analysis approach to missing bolts detection. *Measurement* **2025**, *259*, 119713. <https://doi.org/10.1016/j.measurement.2025.119713>.
246. Marsilio, L.; Barrios, S.; Maksimovic, S.; Maccarini, A.; Serafini, E.; Grimaldi, M.; Heyman, T.J.; Cerveri, P.; Casarin, S.; Don-dossola, E. In silico digital twins of bone metastasis enable investigation of tumor progression and therapy response. *Cancer Res.* **2025**, *85*, 4269–4284. <https://doi.org/10.1158/0008-5472.CAN-25-0088>.
247. Li, W.; Bai, Q.; Zhang, M. SIMiner: A stigmergy-based model for mining influential nodes in dynamic social networks. *IEEE Trans. Big Data* **2019**, *5*, 223–237. <https://doi.org/10.1109/TBDATA.2018.2824826>.
248. Park, S.; Supek, F.; Lehner, B. Higher order genetic interactions switch cancer genes from two-hit to one-hit drivers. *Nat. Commun.* **2021**, *12*, 7051. <https://doi.org/10.1038/s41467-021-27242-3>.

249. Ahsan, A.; McDonald, H.; Saha, R.; Davison, C. When AI Speaks the Curriculum: From Generic Chatbots to Context-Aware Learning Systems. *Systems* **2026**, *14*, 791. <https://doi.org/10.3390/systems14070791>.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.